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SUMMARY 
Intestinal microorganisms are recognized by Toll-like receptors (TLRs), nucleotide-
binding oligomerization domain-containing proteins (NODs) and peptidoglycan recognition 
proteins (PGRPs). PGRPs are a novel family of microbial pattern recognition receptors that 
recognize bacterial peptidoglycan and function in antibacterial innate immunity. The 
mammalian PGlyRP family consists of four members: PGlyRP1, 2, 3 and 4. Many studies 
have focused on the role of TLRs and NODs in immune response, whereas the expression and 
immunological role of PGlyRPs had gained less attention.  
Also, many studies have focused on the intestinal immune modulation by dietary fatty 
acids (FFA), prebiotic products and probiotic bacteria, which are also able to produce short- 
and branched-chain fatty acids (SCFA and BCFA). The mechanisms of this 
immunomodulation are still not fully understood.  
Hypothesising that nutrition and intestinal microbes may be involved in 
immunomodulation through PGlyRPs, the present study aimed to investigate the role of 
bacterial and dietary FFA and prebiotic products in the inflammation in intestinal Caco-2 
cells, and to elucidate the impact of PGlyRP3 in the immune response and inflammation in 
these intestinal cells.  
PCR and Western blot demonstrated the expression of only PGlyRP3 in Caco-2 cells. 
This expression was enhanced by the PPARγ agonist GW1929 and other PPARγ ligands 
(bacterial and dietary FFAs). This result was supported by the observed physical binding of 
PPARγ to the PGlyRP3 promoter, as demonstrated by EMSA. Overexpression / silencing of 
PGlyRP3 decreased / increased gene expression of proinflammatory cytokines (IL-12, IL-8, 
TNF-α). FFAs that induced PGlyRP3 inhibited expression of these cytokines. Silencing of the 
PGlyRP3 gene caused the same FFAs to increase the cytokine gene expression. 
The oligosaccharides α3-sialyllactose and fructo-oligosaccharides (Raftilose p95) 
increased the expression of PGlyRP3, reduced the expression of IL-12 p35, IL-8 and TNF-α, 
and reduced IL-12 release. Both oligosaccharides induced PPARγ expression. PPARγ 
antagonists abolished the oligosaccharide–induced inhibition of cytokines’ expression. 
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Different peptidoglycans (PGNs) increased significantly the expression of IL-12p35, 
IL-8 and TNF-α and the secretion of IL-12, although they enhanced PGlyRP3 expression. 
PGlyRP3 overexpression, together with the inhibition of MyD88, which is a central adaptor 
protein of the TLR pathway, significantly reduced the expression of proinflammatory 
cytokines.  
A negative regulation of the NF-κB pathway, including up-regulation of IκBα and 
down regulation of NF-κB and COX-2, was involved in the anti-inflammatory effects of 
PGlyRP3. 
It is concluded that PGlyRP3 has an anti-inflammatory effect. Oligosaccharides and 
FFAs mediated their anti-inflammatory effect depending on PPARγ and PGlyRP3. Microbial 
PGNs act proinflammatory due to TLR pathway activation, prevailing PGlyRP3’s anti-
inflammatory action. When PGlyRP3 expression is increased, the balance may be shifted 
towards lower levels of inflammation.  
The results of this study imply that nutrition (lipophilic ligands of PPAR, prebiotic 
oligosaccharides) and microbial products (PGNs and FFA) are able to modulate immunity in 
intestinal Caco-2 cells by modulation of PGlyRP3 expession.  
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ZUSAMMENFASSUNG 
Intestinale Mikroorganismen werden von Toll-Like Rezeptoren (TLRs), Nucleotide-
binding Oligomerization Domain-containing Proteinen (NOD) und Peptidoglycan 
Recognition Proteinen (PGRPs) erkannt. PGRPs gehören zur Familie der Pattern Recognition 
Rezeptoren, welche bakterielle Peptidoglykane erkennen und eine Rolle bei der Antwort des 
angeborenen Immunsystems auf Bakterien spielen. Die humane PGlyRP Familie besteht aus 
vier Mitgliedern: PGlyRP1, 2, 3 und 4. Anders als TLRs und NODs ist über die Expression 
und immunologische Funktion der PGlyRPs im Darm kaum etwas bekannt. 
In zahlreiche Studien konnten immunmodulierende Eigenschaften von 
Nahrungsfettsäuren, prebiotische Produkte und probiotische Bakterien, die kurzkettige 
(SCFA) and verzweigtkettige Fettsäuren (BCFA) synthetisieren können, gezeigt werden. Die 
dabei zugrunde liegenden Mechanismen sind aber nur zum Teil aufgeklärt.  
Der Fokus der vorliegenden Arbeit lag auf der durch PGlyRP3 vermittelten 
immunmodulierenden Wirkung von Nahrungsfaktoren und intestinalen Mikroorganismen. 
Die Rolle bakterieller und Nahrungsfettsäuren und prebiotischer Produkten auf 
Entzündungsprozesse wurde in den intestinalen Caco-2-Zellen untersucht. Weiterhin wurde 
der Einfluss des PGlyRP3 auf die Immunantwort und Entzündungsprozesse in diesen 
intestinalen Zellen aufgeklärt.   
In der intestinalen Zelllinie (Caco-2) konnte mittels PCR und Western-Blot die 
Expression des PGlyRP3–Gens gezeigt werden. Diese Expression konnte durch PPARγ 
Agonist GW1929 und Liganden (bakterielle und Nahrungsfettsäuren) induziert werden. 
Dieses Ergebnis wurde durch die beobachtete physikalischen Bindung zwischen PGlyRP3 
Promoter und PPARγ unterstützt, wie EMSA zeigte. Durch Überexpression / Silencing von 
PGlyRP3 wurde die Expression der proinflammatorischen Zytokine IL-8, IL-12 und TNF-α 
unterreguliert / erhöht. FFA, welche PGlyRP3 induzierten, inhibierten die getesteten 
Zytokine. Das Silencing von PGlyRP3 wiederum führte zu einer FFA-vermittelten 
Aktivierung der Zytokinexpression. 
Die Oligosaccharide α-3-Sialyllactose und Fructooligosaccharid (Raftilose p95) 
erhöhten die Expression von PGlyRP3 und inhibierten die Expression von IL-12p35, IL-8 und 
TNF-α und die Sekretion von IL-12. Beide Oligosaccharide induzierten darüber hinaus die 
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Expression von PPARγ, während PPARγ Antagonisten die Oligosaccharid-induzierte 
Inhibierung der Zytokinexpression aufhoben.  
Obwohl die untersuchten Peptidoglykane (PGNs) die Expression von PGlyRP3 
erhöhten, stieg die Genexpression von IL-12 p35, IL-8 und TNF-α sowie die Sekretion von 
IL-12. Die Überexpression von PGlyRP3 und die Hemmung von MyD88 – ein zentrales 
Adaptormolekül des TLR-Signalweges – führten zu einer signifikant geringeren Expression 
proinflammatorischer Zytokine. 
 Eine negative Regulation des NF-κB Signalwegs, gezeigt an der Aktivierung von 
IκBα sowie der Hemmung von NF-κB und COX-2, ist am anti-inflammatorischen Effekt von 
PGlyRP3 beteiligt.  
Die vorliegenden Daten deuten darauf hin, dass PGlyRP3 anti-inflammatische Effekte 
aufweist.  Der Oligosaccharid-vermittelte anti-inflammatorische Effekt ist von PPARγ und 
PGlyRP3 abhängig. Mikrobielle PGNs wirken über den TLR Signalweg proinflammatorisch 
und überdecken dadurch die anti-inflammatorische Wirkung von PGlyRP3. Ist die Expression 
von PGlyRP3 erhöht, verschiebt sich das Gleichgewicht in Richtung einer geringeren 
Entzündungsaktivität. Die Ergebnisse dieser Studie lassen den Schluss zu, dass 
Ernährungsfaktoren (lipophilic ligands, Prebiotika, Oligosaccharide) und mikrobielle 
Produkte (PGNs, Fettsäuren) über PGlyRP3 eine immunmodulierende Wirkung aufweisen.  
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Hypothesis and aim of the work 
The human gut microbiota may contain pathogenic, benign and beneficial 
microbial genera. The former can lead to intestinal disorders that can be acute 
(e.g. gastroenteritis) or chronic (e.g. inflammatory bowel disease). Attempts 
have been made to influence the balance of the gut flora in favor of beneficial 
microorganisms. This is achieved by adding such microbial strains to an 
appropriate food vehicle (probiotic bacteria). Probiotics have been defined as 
non-pathogenic bacteria that, upon ingestion in certain amounts, exert beneficial 
effects for the host (6). Another attempt was the prebiotics. These are defined as 
non-digestible food ingredients (as oligosaccharides) that selectively stimulate 
the growth and activity of beneficial bacteria in the colon leading to beneficial 
health effects (6). Both bacteria and prebiotics interact with the host enterocytes 
in various ways, including their pathogen-associated molecular patterns 
(PAMPs) as lipopolysaccharides and peptidoglycan, and fermentation products 
as short-chain and branched-chain fatty acids (SCFAs and BCFAs). However, 
the pathways of interaction between enterocytes and those products are not 
sufficiently investigated. 
Enterocytes are able to recognize bacterial PAMPs by 3 receptor families: 
Toll-like receptors (TLRs), nucleotide binding oligomerization domains 
receptors (NODs) and peptidoglycan recognition proteins (PGlyRPs). The 
PGlyRPs comprise a novel 4-member-family in mammals that specifically 
recognize peptidoglycans. The gene expression pattern, functions and 
intracellular pathways of PGlyRPs are not studied in enterocytes. On the other 
side, numerous studies are available in the literature concerning the host-
pathogen relationship and focussing on TLRs and NODs. Most of these studies 
were performed with the emphasis to unravel pathways underlying 
immunological reactions of the host. However, no studies were performed from 
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2 
the metabolic point of view. In the present work, it is hypothesised that bacterial 
products, such as some fatty acids, and prebiotic compounds, such as fructo-
oligosaccharides, may exert an immunological response through pathways not 
based on direct ligand binding. It is suggested that this may be mediated by 
transcription factors sensitive to these products, which affect the expression 
level of pattern recognition receptors (PGlyRPs), which in turn exert their 
immunological effect. Therefore, it was the aim of this work to: 
1. Examine which of the PGlyRP genes are expressed in the human colon 
adenocarcinoma cell line (Caco-2) that has been shown to be a useful in 
vitro model for the intestinal epithelium.  
2. Investigate whether a physical binding exists between the promoter 
region of the expressed PGlyRP and a candidate transcription factor 
(PPARγ).  
3. Study the effect of the bacterial products (fatty acids and peptidoglycans) 
as ligands of this transcription factor,  
4. Examine whether certain prebiotic oligosaccharides modulate the 
PGlyRP gene expression, and, 
5. Study the immunological consequences of such interaction. 
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Review of Literature 
The intestinal environment  
The intestine is an important contact surface between the external 
environment and the body. The intestinal barrier function is ascertained mainly 
by intestinal epithelial cells connected by tight junctions (1). These cells import 
luminal nutrients and play a crucial active role in immunity by producing 
antimicrobial peptides and proinflammatory cytokines under the influence of 
pattern-recognition receptors triggered by microbes. In vivo experiments by 
using mouse models showed that any dysfunction in intestinal epithelial cells 
increases the susceptibility to intestinal inflammation (2). 
The intestinal lumen contents play an important role in the intestinal 
homeostasis. The active interaction between microbiota and dietary compounds 
present in the intestinal lumen from one side and the intestinal tissue, and the 
immune system from the other side determine the intestinal immune 
homeostasis. The human colon is colonized by 10
11
-10
12
 bacteria per gram of 
content. Intestinal bacteria could be beneficial for the sake of host’s health, but 
also may be harmful and exert harmful effects such as the initiation of gut 
inflammation. Their composition changes along the intestinal tract. The total 
bacterial content is increasing from the stomach (10
2
)
 
to the colon (10
14
). A 
number of studies have focused on the role of the intestinal flora in modulating 
the immune system (3). Comparisons with germ-free animals suggested that 
low basal inflammation is associated with the maturation of immune system and 
the commensal microbiota. Definitely, the lymphoid tissues are 
underdeveloped, in the absence of flora (4). 
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Intestinal bacteria produce fatty acids 
The microbes that colonize adult intestines function as a metabolic organ 
that complements the human metabolic apparatus. The metabolism of 
carbohydrates and amino acids in the human large intestine due to fermentative 
activity of the gut microbiota yields fatty acids. Short-chain fatty acids (SCFA) 
are the major end products of this fermentation, and include primarily lactate, 
acetate, propionate and butyrate, although formate, valerate, caproate are also 
produced. Some branched-chain fatty acids (BCFA) as isobutyrate, 2-methyl-
butyrate and isovalerate may also result, but in lesser amount than SCFA (5). In 
the human intestine fatty acids are formed by the fermentation of poly or 
oligosaccharide, protein, peptide and glycoprotein precursors by intestinal 
microorganisms (6). 
Fatty acid formation by intestinal bacteria is regulated by many different 
environmental, host, dietary and microbiological factors. Readily-digestible 
carbohydrates and the period that digestive material spends in the colon affect 
types and amounts of SCFA produced (7). It was also found that long time 
exposure of food ingredients in the large intestine can have great effects on 
bacterial metabolism, leading to protein and amino acid fermentation into 
SCFA, which, in turn, increase SCFA in colon (8). SCFA concentrations are 
highest in the proximal large intestine, mainly because of greater carbohydrate 
availability. Studies using intestinal material obtained from human sudden death 
victims found that acetate, propionate, butyrate values were similar in different 
regions of the large intestine (9). However, subsequent studies showed that 
bacterial fermentation products vary in different regions of the colon both 
qualitatively and quantitatively (10). 
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Dietary fatty acids are known to modulate immune responses in 
the intestine 
It has been reported that intestinal epithelial cells produce various 
inflammatory mediators by different intra-luminal stimulants, and participate in 
the development of intestinal inflammation (11, 12). A close relationship 
between fatty acids and intestinal inflammation has also been reported. Tanaka 
et al. (13) showed that both oleic and capric acids (C10) enhanced IL-8 
production in the intestinal Caco-2 cells after incubation for 3 and 6 hrs, 
whereas decosahexaenoic and eicosapentaenoic acids did not. Andoh et al. (14) 
found that in intestine-407 cells octanoic acid (C8) increased IL-1b-induced IL-
8 secretion in dose-dependent manner, whereas capric acid micelles (C10) did 
not, contrasting the results of Tanaka et al. (13). Mariadason et al. (15) have 
shown that SCFA maximally induced a number of endpoint read-out analyses 
including IL-8 secretion in undifferentiated Caco-2 cells, but had a different 
effect in differentiated Caco-2 cells. On the other hand, an anti-inflammatory 
effect of the n-3 long-chain fatty acids (LCFA) has been reported in patients 
with the inflammatory Crohn’s disease (16). It has also been suggested that n-3 
PUFAs are beneficial in ameliorating chronic inflammatory diseases (17). A 
low-fat diet has often been used as a therapy of different gastrointestinal 
diseases. Linoleic acid, but not oleic acid, caused a marked increase in the 
secretion IL-8 by human intestinal smooth muscle cell from Crohn’s disease 
patients. Treatment of normal cells with Linoleic acid did not induce 
translocation of NF-κB nor IκB-α, and treatment of cells from Crohn’s disease 
patients did not induce further translocation. Linoleic acid stimulated IL-8 
production only in cells of Crohn’s disease but not in normal cells. Thus, 
linoleic acid increased the production of IL-8 only in situations where NF-κB 
was activated (18). 
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The interaction between intestinal epithelial cells and microbes 
Pathogen-associated molecular patterns (PAMPs) or microbe-associated 
molecular patters (MAMPs) are common motifs found in microorganisms but 
not in eukaryotes. Bacterial PAMPs include lipopolysaccharide (LPS) from 
Gram-negative bacteria, peptidoglycans (PGNs) from both Gram-positive and 
Gram-negative bacteria, and lipopeptides from various bacteria. The innate 
immune system consists of specific receptors which known as pattern 
recognition molecules (PRMs) discriminate between microorganisms and self 
by recognize PAMPS (19).  
Peptidoglycan recognition is a key event in the innate immune response 
in mammals. PGNs are essential constituents of the cell walls of Gram-positive 
and Gram-negative bacteria. The minimal essential structure of PGN to induce 
cell-mediated immunity was chemically synthesized and designated 
muramyldipeptide (MDP). Nucleotide binding oligomerization domains NOD1 
and 2, proteins were demonstrated to be intracellular receptors for MDP (20, 
21). In fact, two families of proteins mediate peptidoglycan recognition; these 
are the PGlyRP and Nod proteins. Whereas the Nod proteins Nod1 and Nod2 
are cytoplasmic proteins, mammalian PGlyRP likely detect peptidoglycan in 
different cellular compartments owing to the fact that they are membrane-
bound, stored in vesicles, or secreted proteins. Nod1 and Nod2 are involved in 
innate immune defence through pathways that are likely to be independent of 
TLR signalling. Nod1 is an upstream activator of NF-B. Nod1 pathway 
activation leads to proinflammatory cytokines production, such as IL-8. Nod1 
was first described as an intracellular receptor for LPS. Afterwards, PGN 
exclusively from Gram-negative bacteria was demonstrated to be the real 
agonist of Nod1 (22, 23). It is now clear that Nod1 is a sensor for both Gram-
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positive and Gram-negative bacteria that have mesodiaminopimelic acid (DAP)-
type peptidoglycan in their wall, Nod2 is able to induce NF-B activation as 
well as Nod1. However, unlike Nod1, Nod2 is able to sense L-lysine (LYS)-
type peptidoglycans in Gram-positive and Gram-negative bacteria cell walls 
(24). After recognition of PGN fragments via Nod2, NF-B activation leads to 
production of cytokines such as IL-1, IL-6 and TNF-α (25). 
It should be mentioned that PGN is also recognized by a membrane-
bound PRM, the Toll-like receptor (TLR2) (26), although an intact glycan chain 
of PGN is required for TLR2 to recognize PGN, therefore TLR2 could not 
recognize free MDP (27). 
 
Peptidoglycan Recognition proteins 
There is a novel family of pattern recognition molecules (PRMs) called 
Peptidoglycan recognition proteins (PGRPs). These PGRPs are highly 
conserved from insects to mammals (28, 29). PGRPs were first identified in the 
silk worm Bombyx mori, which identified as a protein that found in the 
hymolymph and binds to Gram-positive bacteria this in turn activates an 
immune response (30). Thereafter different PGRPs were identified in insects, 
and were classified according to their length into two classes, short PGRPs 
(PGRP-S) and long PGRPs (PGRP-L) (31, 32).  
Insect PGRPs bind directly to PGN, each with separate favourites for 
Lys-PGN or DAP-PGN results in activation of two different immune signalling 
pathways (Toll and Imd). All PGRPs contain a conserved PGRP domain region, 
which has homology to bacteriophage T7 lysozyme and bacterial type two N-
acetylmuramoyl-L-alanine amidase and are predicted to have amidase activity. 
In Drosophila, there are 13 PGRPs, which are expressed in different organs, 
General Introduction 
 
 
 
8 
such as the fat body and gut. and up-regulated by PGN (33), suggesting critical 
roles in host defense against microbial infections in insects. Drosophila PGRP-
SA is required for the activation of the Toll receptor pathway by Gram-positive 
bacteria, which results in the induction of anti-bacterial peptides and the 
generation of an effective immunity to Gram-positive bacteria (34). Drosophila 
PGRP-LC participates in the induction of anti-bacterial peptides in response to 
Gram-negative and Gram-positive bacteria (35). PGRP-LE is involved, in 
addition to its anti-bacterial defense, in the activation of a prophenoloxidase 
cascade in response to the diaminopimelic acid (DAP)-type PGN from most of 
Gram-negative and some Gram-positive bacteria (36). In general the insect, 
PGRPs with amidase activity have anti-inflammatory role and reduce the 
inflammatory effect of peptidoglycan (37- 39). Thus, insect PGRPs play 
important roles in innate immune responses to bacteria. 
 In mammals, PGRPs from human (40), mouse (41), rat (42), cow (43) 
and camel (44) have been described. Recently, four human PGRPs designated 
PGRP-S (PGlyRP1) (41), PGRP-L (PGlyRP2), PGRP-Iα (PGlyRP3) and 
PGRP-Iβ (PGlyRP4) (40) were identified. Liu et al. (45) described the 
functional similarity of PGRPs from mammals to that in insects. They reported 
that a mouse recombinant PGRP, probably PGRP-S bound to Staphylococcus 
aureus PGN and some Gram-positive bacteria and exhibited a bacteriostatic 
activity against Gram-positive bacteria, but not against Gram-negative bacteria 
such as Escherichia coli. Dziarski et al. (2003) (46) described that PGRP-S 
mRNA was predominantly expressed by polymorphonuclear leukocytes 
(PMNs) in mice and humans, and that PGRP-S inhibited phagocytosis after the 
infection with Gram-positive bacteria, as well as inflammatory cytokine 
production in response to PGN in macrophages. PGRP-S-deficient mice were 
more susceptible than wild-type mice upon intraperitoneal infection with 
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bacteria. They also reported the defective intracellular killing of bacteria in 
PMNs from PGRP-S knockdown
 
mice.  
The family members show selective and differential expression; PGRP-S 
(PGlyRP1) is highly expressed in bone marrow, PGRP-L (PGlyRP2) in the 
liver, and PGRP-Iα and PGRP-Iβ (PGlyRP3 and 4) in the oesophagus (40). 
Their distinct expression patterns suggest that each may play a unique role in 
host defence. Consistent with the presence of a PGRP domain, each human 
PGlyRP is able to bind Staphylococcus aureus PGN and whole cells of Bacillus 
subtilis and Micrococcus luteus with high affinity (40). Concerning PGlyRP3, 
the crystal structure of the C-terminal PGN binding site has been exhaustively 
characterized (47). Both murine (48) and human (49) PGRP-L exhibited lytic 
activity towards PGN. Even though all four members have the PGlyRP domain, 
only one mammalian PGlyRP, PGlyRP-L, has been reported to have amidase 
activity. It is an MurNAc-L-Ala amidase, which allows this enzyme to cleave 
PGN between the sugar moiety and the peptide moiety (48). All mammalian 
PGlyRPs have been shown to be proteins that bind directly to PGN as well as 
live bacteria. Their mRNA expression increased significantly by synthetic 
PAMPs. Suppression of the expression of TLR2, TLR4, NOD1, NOD2 RNA 
interference specifically inhibited the upregulation of PGlyRPs mRNA 
expression induced by different synthetic PAMPs (26). 
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ABSTRACT 
PGlyRPs recognize bacterial peptidoglycan and function in antibacterial 
innate immunity. Focusing on the interference between nutrition and 
recognition pattern proteins, free fatty acids (FFA) of dietary and bacterial 
sources may exert their immunological response through modulating the 
expression level of the PGlyRPs in enterocytes. PGlyRP3 was the only 
PGlyRPs’ member expressed in Caco-2 cells. In silico analysis showed that the 
promoter of PGlyRP3 has some PPRE regions that, as tested by EMSA, bind 
physically to the PPARγ-RXRα complex. PGlyRP3 gene expression was 
induced by PPARγ ligands including GW1929 and some FFA. Overexpression 
of PGlyRP3 in Caco-2 cells down regulated the expression of the inflammatory 
cytokines IL-8, IL-12 and TNF-α, while its silencing increased the expression of 
these cytokines. FFA that induced the PGlyRP3 inhibited the tested cytokines. 
Silencing of PGlyRP3 gene caused the same FFA to increase the cytokine gene 
expression. A negative regulation of NF-κB pathway, including up-regulation of 
IκB-α and down regulation of NF-κB and COX-2, is involved in the anti-
inflammatory effects of PGlyRP3. In conclusion, PPARγ mediates a modulation 
of PGlyRP3 gene expression, which is involved in inhibiting inflammation 
through negative regulation of NF-κB pathway.  
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INTRODUCTION 
“Inflammation is the body’s immediate response to damage of its tissues 
and cells by noxious stimuli such as chemicals or physical injury and 
pathogens” (1). The human colon is colonized by 1011-1012 bacteria per cm3. 
Intestinal bacteria may be beneficial provide the host health or harmful exert 
adverse effects such as the gut inflammation and the activation of precursors of 
toxic food components. Metabolization of carbohydrates and amino acid due to 
fermentative activity of the gut microflora yields short chain fatty acids (SCFA) 
as acetic, propionic, butyric, valeric, and caproic acids, and some branched-
chain fatty acids (BCFA) as isobutyric and iso-valeric acids (2, 3). These have 
been associated with reduced risk of some diseases, including the irritable 
bowel syndrome, inflammatory bowel disease and cancer (4).  
The interaction between intestinal epithelial cells and microbes is partly 
mediated by members of the Toll-like receptor family (TLRs), the family of 
nucleotide-binding oligomerization domain-cotaining proteins (NODs) and the 
peptidoglycan recognition protein family (PGlyRPs). TLRs play a essential role 
in the detection of invading microorganisms and the induction of immune 
response and inflammatory signalling pathway to defend the host (5, 6). NODs 
and PGlyRPs also recognize bacteria, and interact with pro-inflammatory 
signalling pathways (7).  
Dietary FFAs are known to modulate immune responses. It has been 
suggested that n-3-PUFAs are beneficial in ameliorating chronic inflammatory 
diseases (8). Some reports have focused on the interference between nutrition 
and recognition pattern proteins, especially TLRs and NODs. Lauric acid 
(C12:0) dose dependently activated NF-κB and induced IL-8 expression. 
Conversely, decosahexaenoic acid (DHA), an n−3-PUFA, inhibited NF-κB 
activation and IL-8 expression. These effects were inhibited by dominant 
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negative forms of NOD1 and NOD2, but not TLR2, TLR4 or TLR5 (9). In 
another study, the increasing levels of nutritional FFA in obesity were 
associated with activation of TLR4 signalling in adipocytes and macrophages 
(10). The capacity of FFA to induce such inflammatory signalling in adipose 
cells and macrophages is blunted in the absence of TLR4 (10). FFA can activate 
TLR4 signalling and subsequent NF-κB-activation to regulate adipokine and 
chemokine secretion from adipocytes (11). Thus, nutritional components may 
initiate some immunological events through interaction with NODs and TLRs. 
However, the underlying mechanisms for the effects of dietary or microbial 
FFA remain unclear. In addition, no information is existing about PGlyRPs, the 
third pattern recognition receptor family, regarding their modulation by FFA. 
PGlyRPs are innate immunity proteins that are conserved from insects to 
mammals (12). They recognize bacterial peptidoglycan and function in 
antibacterial innate immunity. Mammals have four PGlyRPs named PGlyRP1, 
2, 3, and 4. There are only two known functions of mammalian PGlyRPs. 
PGlyRP1, which is expressed in PMN’s granules, as well as PGlyRP3 and 4, 
which are found in many organs, have direct bactericidal effect. PGlyRP2, 
which is an N-acetylmuramoyl-L-alanine amidase , it is highly expressed in the 
liver and secreted into blood, that hydrolyzes peptidoglycan (13). PGlyRPs, 
NODs and TLRs, represent three different types of pattern-recognition 
receptors, playing interdependent in vivo roles in local inflammation (13). 
The effects of FFA are mediated either directly due to their specific 
binding to various nuclear receptors leading to changes in the activity of these 
transcription factors, or indirectly as the result of changes in the abundance of 
regulatory transcription factors (14). Peroxisome proliferator-activated receptors 
(PPARs) are members of the nuclear hormone receptors super-family of ligand-
activated transcription factors that are related to retinoid, steroid, and thyroid 
hormone receptors. So far, three different PPAR subtypes have been identified 
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and are commonly designated as PPARα, PPARβ and PPARγ. The PPARγ 
plays a pivotal role in the regulation of lipid metabolism and control of 
inflammation (15), since PPARγ is associated with anti-inflammatory responses 
(16). PPARs are activated by different FFA and there metabolites, indicating
 
that PPARs act as fatty acid sensors (17). PPARγ has been shown to regulate 
cell activation, differentiation, proliferation, and/or apoptosis (16) and 
ameliorate inflammation in Bowel disease (18).  
Many studies have focused on the inflammatory pathways that are 
downstream of the recognition patterns. However, less focus was put on its 
interactions with fatty acid metabolism. We hypothesise that FFA of nutritional 
and bacterial sources exert an immunological response, which could be 
mediated by transcription factors of lipophilic ligands, thus affecting the 
expression level of some recognition patterns. We therefore examined which of 
the PGlyRP genes are expressed in the human colon adenocarcinoma cell line 
(Caco-2) that has been shown to be a useful in vitro model for small intestinal 
epithelium (19), and determined the expression of PGlyRP3. We further 
investigated whether a physical binding exists between the promoter region of 
PGlyRP3 and lipid transcription factors as PPARs. Additionally, we studied the 
effect of the lipophilic ligands of these transcription factors on PGlyRP3 gene 
expression, and the immunological consequences of such an effect.  
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MATERIAL AND METHODS 
 
Cell culture  
 Caco-2 cells were obtained from the American Type Culture Collection 
Company (ATCC). Cells between passages 10-50 were grown in 75 cm² culture 
flasks at 37°C and 5% CO2 using Minimum Essential Medium (MEM + 
Glutamax, Invitrogen, Karlsruhe, Germany) supplemented with 20% fetal calf 
serum, 100 IU penicillin/ml and 1% non-essential amino acids. For different 
experiments, cells were cultured in 6 well plates until reaching 7 days post 
confluence. Cells were fasted for 2 hours in Minimum Essential Medium (MEM 
+ Glutamax) without any supplementations before different incubations. For 
over-expression and RNA-silencing experiments, cells were cultured in 24-well 
plates until reaching 80-100% confluence. 
 
In silico analysis  
The promoter region of the human PGlyRP3 gene has been inspected for 
the presence of transcription factors of lipophilic ligands. A 2-kB region of the 
promoter sequence upstream to the transcriptional coding sequence of the 
human PGlyRP3 gene was taken from the Ensembl database 
(www.ensembl.org). For the prediction of putative transcription factor binding 
sites, the in silico analysis of the PGlyRP3 promoter using the TRANSFAC 
Professional Database (www.biobase.de/pages/products/transfac.html) was 
performed. A core similarity of 0.85 or greater and a matrix similarity of 0.90 or 
greater were defined as a cut-off for consideration of potential query sequence 
matches. 
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Electron mobility shift assay (EMSA) 
The nuclear protein was extracted from Caco-2 cells and transfected Hela 
cells using the kit from Active Motif (Rixensart, Belgium). To transfect Hela 
cells with PPARγ, cells were seeded to a confluency of 50-70%. One hundred 
ng PPARγ plasmid DNA was added. The transfection method was similar to 
that of PGlyRP3 transfection (see below). EMSA was performed using 
LightShift chemiluminescent EMSA kit (Pierce). DNA-oligonuleotides 
including the predicted putative binding sites for PPAR and RXR were ordered 
as single stranded 3′-end labelled with biotin or non-labelled from MWG 
Biotech (Ebersberg, Germany) (supplementary data, table 1, the underlined 
letters indicate the putative PPRE sequence). The double strand probes were 
prepared by annealing 3′-end biotin- labelled and non-labelled oligonucleotides. 
The DNA-protein binding assay was performed at room temperature for 30 min 
in a final volume of 20 μl containing 1x binding buffer, 2.5% glycerol, 0.1 mM 
EDTA, 1 μg of poly (dI-dC), 10.fmol of double-stranded biotinylated probe, and 
10 μg of nuclear extract. For the competition assay, 100x (2 pmol) of non-
labelled oligonucleotide were included in the binding reaction (Fig. 2, lane 3). 
For supershift EMSA, 2 μl of PPARγ monoclonal antibody (Fig. 2, lane 4) or 2 
μl of RXRα polyclonal antibody (Fig. 2, lane 5) (Santa Cruz Biotechnology 
Heidelberg, Germany) were preincubated in the binding reaction for 30 min 
before the probe was added. The DNA-protein complexes were separated by 4% 
PAGE in 0.5× TBE at 200 V in Ice for 2 h. DNA-protein complexes in gel were 
transferred to Hybond N+ nylon membrane (Amersham Biosciences) by 
electroblotting with 0.5× TBE at 350 mA for 1.5 h. DNA-protein complexes 
were fixed to the membrane by UV cross-linker and detected by incubation of 
the membrane with the substrate solution and then exposure to radiographic 
film. 
 
PPARγ-dependent PGlyRP3 expression regulates proinflammatory cytokines by 
microbial and dietary fatty acids 
 
 23 
Preparation of fatty acids and incubations 
Palmitic (C 16:0), oleic (C 18:1), linoleic (C 18:2), eicosapentaen acid (C 
20:3) (EPA), 13-methylmyristic acid (C 15), 15-methylpalmitic acid (C 17), 
phytanic acid were purchased from Sigma. Stock solutions were prepared by 
dissolving the FFA in 5% bovine serum albumin (BSA) to a final concentration 
of 3 mM after incubation in ultrasonic bath.  
Fasted cells were incubated for 24 hours with one of the different FFA at 
a concentration of 100 µmol/l. Control incubations were supplied with the 
vehicle only (final concentration of BSA is 0.05%).  For examining the effect of 
PPARγ, the PPARγ agonist GW1929 (Sigma) was dissolved in 
dimethylsulphoxide (DMSO, final culture concentration 0.1%) and added to 
make a final concentration of 10 µmol/l. Control  culture were supplied with 0.1 
% DMSO. 
 
RNA isolation, cDNA synthesis, and real time PCR  
 Total RNA was isolated from Caco-2 cells using RNeasy kit (Qiagen, 
Hilden, Germany). To assure absence of genomic DNA, all RNA samples were 
treated with DNase-1, and multiple exons-spanning primers were used for PCR 
amplification. For reverse transcription, 1 µg of the total RNA was reverse 
transcribed to first strand complementary DNA in 25 µl reactions using the 
cDNA synthesis Taqman kit (Applied biosystem). RT-PCR analysis of PGlyRP 
genes expression in addition to β-actin as a household gene was performed 
using specific primers for each gene (see table 1; for PGlyRP1, 2 and 4, we used 
primers as reported by Liu et al (20). PCR products were electrophoresed on 
agarose gel and their bands were visualised by ethidium bromide staining. 
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Quantitative real time PCR analysis  
All quantitative RT-PCR analyses were performed on an Applied 
Biosystems ABI Prism 7000 system using cDNA samples corresponding to 20 
ng RNA. Quantitative analysis of PGlyRP3 gene expression was undertaken by 
using TaqMan gene expression assay in a 30 µl reaction with universal PCR 
master mix and TaqMan MGB probe (No. Hs 01074825_ml, Applied 
Biosystems, Cambridge, UK). To normalize expression data, β- actin was used 
as an internal control gene. Data are presented as fold difference from control, 
considering the control values as 1. 
Quantitative RT-PCR analyses of all other studied genes were performed 
using SYBR Green (Power SYBR green Mastermix, Applied Biosystems). All 
studied genes were quantified within the same cDNA samples. The thermal 
cycling program was 10 min at 95°C for enzyme activation and denaturation for 
15 s at 95°C, 60 s annealing at 60°C. A dissociation curve was performed for 
each product to assure the absence of primer dimers or unspecific products. 
Primers used in the present study are listed in table 1 (supplementary data). To 
normalize expression data, β-actin was used as an internal control gene. Data 
are presented as fold difference from control, considering the control values as 
1. 
 
Transfection of Caco-2 cells with PGlyRP3 plasmid 
RNA was isolated from human oesophagus (approved by the ethics 
committee of the Christian-Albrechts-University of Kiel “protocol A 120/05”) 
and using the designed primers (supplementary data, table 1), full-length 
cDNAs coding for PGlyRP3 was cloned. We designed oligonucleotide primers 
after testing the sequences for restriction enzymes (Xho1 and EcoR1) that 
neither cut within the PGlyRP3 nor the vector sequences. The PCR products 
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were ligated into the pCAGGS vector (T4-Ligase Rapid-Kit(Fermentas, 
Karlsruhe, Germany), and clones with the proper full-length PGlyRP3 insert 
were selected and identified by restriction digestion and sequencing the inserts. 
The cloned PGlyRP3 was identical to the genomic sequences. 
Caco-2 cells were seeded in a 24-well plate at a density of 4˟104 cells per 
well in 1 ml of culture medium and transfections performed at 60–80% cell 
confluence. Prior to transfection, TurboFect (Fermentas) and MEM (Invitrogen) 
were mixed and incubated at room temperature for 20 mins. 100 ng DNA was 
added in a ratio of 3:1 (TurboFect in µl: DNA in ng) as recommended by the 
manufacturer. Control samples were treated similarily and transfected with the 
empty vector (pCAGGS). After 48 and 72 hrs post transfection, RNA was 
isolated and reverse transcribed to cDNA. PGlyRP3 gene overexpression was 
confirmed using quantitative RT-PCR and Western blot (supplementary data, 
Fig. S1).  
 
Small interfering (si) RNA experiments 
Two siRNA sequences targeting PGlyRP3 (Si Select si RNA no. s41580 
and s41581) and a non-targeting negative control sequence (SC 4390843) were 
purchased from (Ambion, Applied Biosystems). Caco-2 cells were reverse 
transfected with a mixture of the two siRNA using siPORT NeoFX Transfection 
Reagent (Ambion, Applied Biosystems). siRNA was prepared in Opti-MEM 
serum-free medium (Invitrogen) by mixing 2 µl of the transfection reagent with 
5 nM siRNA, respectively, at room temperature for 10 min. Caco-2 cells (4˟104 
cells per well) were transferred to a 24-well plate containing siRNA transfection 
reagent complexes, allowing transfection to occur during initial cell adherence. 
The medium was replaced after 24 hrs by a culture medium containing 20% 
FCS (allowing cell recovery) and incubation continued for additional 24 and 48 
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hrs, then RNA was isolated and reverse transcribed to cDNA. PGlyRP3 gene 
knock-down was confirmed by quantitative RT-PCR and Western blot 
(supplementary data, Fig. S1).  
 
Protein extraction and Western blot analysis 
The cell lysates were loaded into 12% SDS-PAGE and blotted onto 
PVDF transfer membrane. Membranes were blocked with a mixture of 2.5% 
BSA and 2.5% skimmed milk and incubated with mouse monoclonal anti-
human PGlyRP3 (1:200, AXXORA, Lörr, Germany), rabbit polyclonal anti-
human NF-κB (p65) (1:200, Panomics, Affymetrix), rabbit polyclonal anti-
human GAPDH (1:500, Santa Cruz Biotechnology) or rabbit polyclonal anti- 
human Histone3 (H3) (1:2000, abcam). Immunoreactive bands were detected 
with HRP-conjugated secondary antibody. 
 
Interleukin 12 protein assay 
 The human total IL-12 was detected using an ELISA kit ( Mabtech AB, 
Hamburg, Germany) in the supernatant obtained from Caco-2 cell cultures after 
each treatment according to the manufacturer's instructions.  
 
TransAm assay for NF-κB nuclear localization  
 Caco-2 cells were transfected with PGlyRP3 plasmid or siRNA for 48 hrs 
or were incubated  with 10 µmol/l GW1929, 100 µmol/l oleic or 100 µmol/l 
palmitic acids for 24 hrs. Thereafter, nuclear extracts were prepared using a 
nuclear extraction kit (Panomics, Affymetrix, Heidelberg, Germany) according 
to manufacturer’s instructions. Nuclear localization of NF-κB was quantified 
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using Transcription Factor ELISA kit (TransAm) to detect activated p65 subunit 
of NF-κB as illustrated in (Panomics, Affymetrix) user manual.  
 
Statistical analyses 
 All samples were measured in duplicates. Values were expressed as mean 
± S.E.M. with n ≥ 4 in all experiments and p indicated in the Results section. 
Group statistical comparisons were performed by one-way analysis of variances 
(ANOVA) followed by Mann-Whitney (Wilcoxon) multi-range analysis as a 
post-hoc test. A statistical difference was considered significant if p<0.05. 
 
 
RESULTS 
 
Detection of PGlyRP3 gene and protein in Caco-2 cells 
We first sought to determine which PGlyRP is expressed in Caco-2 cells. 
For this purpose, RNA was isolated from Caco-2 cells and processed for RT-
PCR amplification using primers of PGlyRPs listed in table 1(supplementary 
data). RT-PCR analysis of the 4 PGlyRP genes revealed that only PGlyRP3 is 
expressed in Caco-2 cells (Fig. 1A). Since it is known that the expression level 
of some genes differs during the differentiation of Caco-2 cells in culture, we 
isolated RNA from Caco-2 cells at different stages after reaching confluence. 
Normal and quantitative RT-PCR of those samples indicate that PGlyRP3 gene 
expression varies during Caco-2 cell differentiation, reaching a peak on the 
twelfth day and decreasing thereafter (Fig. 1C). The expression of PGlyRP3 
was also confirmed by Western blot analysis (Fig. 1B).  
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Figure 1. Detection of PGlyRP3 gene expression in Caco-2 cells: A) Only 
PGlyRP3 gene is expressed by Caco-2 cells. RNA was isolated from Caco-2 
cells and analysed by RT-PCR for the expression of the 4 PGlyRPs types. B) 
Detection of PGlyRP3 protein in Caco-2 cells by Western blot: Caco-2 cells 
were lysed and equal protein amounts were loaded. The membranes were 
incubated with mouse anti-PGlyRP3 serum (1:200), and immunoreactive bands 
were detected with anti-mouse secondary antibody. C) PGlyRP3 gene 
expression level varies during Caco-2 cell differentiation. RT-PCR was applied 
using mRNA isolated from Caco-2 cells during the mentioned days after 
confluence (DAC). Quantitative RT-PCR analysis for the expression of 
PGlyRP3 in Caco-2 cells during its differentiation was performed using 
PGlyRP3 TaqMan MGB probe. Data was normalized to the expression of β-
actin household gene. The shown data (mean ± SEM) are averages of 3 
separate experiments performed in duplicates.  
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PPARγ and PPARγ-RXRα complex bind to PGlyRP3 promoter 
We have inspected the promoter region of the human PGlyRP3 gene for 
the presence of response elements of transcription factors binding lipophilic 
ligands. The in silico analysis using TRANSFAC data demonstrated the 
presence of several putative binding sites for PPARγ and  PPARγ-RXRα 
complex (PPRE) on the PGlyRP3 gene promoter at different sites (for example  
at -1359, -801, -309 and -178). One of these putative binding sequences (-1359) 
was chosen to test the physical binding ability of PPARγ and PPARγ-RXRα 
complex to the human PGlyRP3 gene. To determine whether the PPARγ or 
PPARγ-RXRα complex are capable of binding the -1359 region of the PGlyRP3 
promoter, we performed an electrophoretic mobility shift assay (EMSA) using 
nuclear extracts obtained from Caco-2 (Fig. 2A). 
As shown in Fig. 2A, lane 2, the biotin labelled double-stranded probe, 
when incubated with nuclear extract from differentiated Caco-2 cells forms 
DNA-protein complexes (shift). Incubation of the Caco-2 nuclear extract and 
biotin labelled double-stranded probe with the antibody against PPARγ or 
RXRα supershifted one of these complexes to higher molecular weight position 
(Fig. 2A, lanes 4 and 5, respectively). This indicated that one of the above 
complexes (lane 2) was formed between the PPRE in the PGlyRP3 promoter 
and the PPARγ/RXRα. However, there were some nonspecific complexes 
formed between PPRE sequence and other transcription factors. It was 
previously shown that the PPRE sequence is able to bind in vitro the PPARs, 
HNF4α, PPARγ /β/α-RXRα complexes , and RXRs  (21- 23).  Similarly, DNA-
protein complex (shift) was formed when biotin labelled double-stranded probe 
was incubated with nuclear extracts prepared from transfected Hela cells with 
PPARγ plasmid (Fig. 2B, lane 2). Incubation of nuclear extracts of these cells 
and biotin labelled double-stranded probe with antibody against PPARγ 
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supershifted the complex (Fig. 2B, lane 4). This experiment confirms the 
binding that occurred in Caco-2 cells.  
 
 
 
Figure 2. PPARγ and RXRα bind to PGlyRP3 promoter: EMSA was applied to 
detect  the in vitro binding of nuclear PPARγ protein to PGlyRP3 promoter 
sequence. A) Nuclear protein extracts from Caco-2 cells were mixed with 
PGlyRP3 double strand  labelled probe  in the presence (lane 3) or absence of a 
100x unlabelled probe. The 30bp-probe was extracted from the PGlyRP3 
promoter region and has a putative binding ability to the mentioned nuclear 
proteins. Mobility retardations (supershift) in the presence of an antibody 
against PPARγ and RXRα are shown in lanes 4 and 5, respectively. B) Nuclear 
protein extract from Hela cells transfected with PPARγ plasmid was mixed 
with PGlyRP3 double strand probe. A supershift in the presence of an antibody 
against PPARγ is shown in lane 4.  
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PGlyRP3 gene expression is regulated by a PPARγ agonist and 
different FFA  
 Then we investigated the regulation of PGlyRP3 gene expression by a 
specific PPARγ agonist in Caco-2 cells (GW1929) for 24 hrs. PGlyRP3 gene 
expression was significantly enhanced by treatment with GW1929 (1.89±0.26) 
(P < 0.003) (Fig. 3A). Western blot analysis showed an increase of PGlyRP3 
protein after treatment with GW1929 for 24 hrs (Fig. 3A, lower panel). 
Next we examined the regulation of PGlyRP3 gene expression in Caco-2 
by different FFA. Caco-2 cells were incubated for 24 hrs with 100 µM of either 
palmitic acid (16:0), a saturated FFA; oleic acid (18:1), a monounsaturated 
FFA; linoleic acid (18:2), an omega-6 polyunsaturated FFA; eicosapentaenoic 
(EPA); an omega-3 polyunsaturated FFA; 13-methylmyristic acid (C15) and 15-
methylpalmitic acid (C17), branched-chain fatty acids (BCFA) and phytanic 
acid, a short-chain fatty acid (SCFA). Differential effects of different FFAs on 
PGlyRP3 protein and gene expressions were observed (Fig. 3B). PGlyRP3 gene 
expression increased to 1.91±0.21 by palmitic, 3.13±0.63 by oleic, 2.19±0.36 by 
EPA, 2.50 ±0.44 by C15, and 1.89 ±0.25-folds by phytanic acid compared with 
control experiments (p < 0.05). On the other hand, PGlyRP3 mRNA levels were 
not affected by linoleic acid or by C17 (1.09±0.09 and 1.20±0.16-folds, 
respectively (p > 0.05) compared with control experiments. 
 
FFA regulate PGlyRP3 gene expression through PPARγ  
To prove this, we investigated the PGlyRP3 expression in Caco-2 cells 
treated with palmitic or oleic acids in the presence or absence of 10 µmol/l of 
the PPARγ antagonist GW9662 (Fig. 3C). 
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The FFA–induced expression (Fig. 3C, upper panel) of PGlyRP3 
(2.30±0.03 and 3.36±0.03-folds for palmitic and oleic acids, respectively, 
compared to the control without FFA) was abolished by the co-incubation with 
the PPARγ antagonist GW9662 (0.96±0.02 and 1.04±0.04-folds, respectively, 
p<0.05). This effect was also remarkable for PGlyRP3 protein (Fig. 3C, lower 
panel).  
 
FFA modulate the gene expression of the cytokines IL-8, IL-12p35 
and TNF-α 
 We measured the mRNA level of interleukins 8, 12p35 (IL-8, IL-12p35) 
and tumor necrosis factor-α (TNF-α) in Caco-2 cells treated with different FFAs 
at concentration of 100 µM for 24 hrs (Fig. 4). Linoleic, oleic, C15, EPA and 
phytanic acids significantly (p<0.05 inhibited IL-8 to 0.20±0.02, 0.35±0.05, 
0.55±0.02, 0.65±0.01 and 0.64±0.02, respectively; IL-12p35 to 0.61±0.03, 
0.59±0.04, 0.68±0.02, 0.70±0.02 and 0.54±0.02, respectively; and TNF-α genes 
expression to 0.78±0.06, 0.64±0.04, 0.73±0.04, 0.72±0.02 and 0.54±0.07, 
respectively. Palmitic acid significantly induced the gene expressions of IL-8 to 
1.60±0.12, IL-12p35 to 1.48±0.18 and TNF-α to 2.38±0.45. C17 acid inhibited 
IL-8 gene expression to 0.72±0.05, (p<0.05), while it has no effect on IL-12p35 
and TNF-α gene expressions (0.95±0.1 and 1.19±0.16, respectively). 
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Figure 3. PPARγ and FFA regulate PGlyRP3 gene expression in Caco-2 cells: 
Caco-2 cells were treated with PPARγ agonist GW1929, antagonist GW9662 
or different FFA. After incubation for 24 hr, the expression of PGlyRP3 gene 
was assessed by quantitative RT-PCR. Results are expressed as relative to β-
actin mRNA as internal standard. The shown data are averages of 6 separate 
experiments performed in duplicates. Western blot analysis was applied to 
samples of the same treatments. (A) The PPARγ agonist GW1929 (10µM) 
induces the PGlyRP3 gene (upper panel) and protein (lower panel) expressions 
in Caco-2 cells after culture for 24 hrs. (B) FFA (100 µM) differentially 
regulate PGlyRP3 gene (upper panel) and protein (lower panel) expressions. 
(C) The PPARγ antagonist GW9662 (10µM) inhibits the palmitic and oleic 
acid–induced PGlyRP3 gene expressions (upper panel) and protein (lower 
panel). Statistical analysis: ANOVA;* denotes p<0.05 in comparison to the 
control cultures. 
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PGlyRP3 down-regulates inflammatory cytokine expression in 
Caco-2 cells  
 We next tried to evaluate whether PGlyRP3 was involved in the 
inflammatory response. Caco-2 cells were transfected with PGlyRP3 plasmid or 
pCAGGS empty control vector for 48 and 72 hrs. PGlyRP3 gene 
overexpression was confirmed after 48 and 72 hrs post-transfection by 
quantitative RT-PCR and Western blotting (supplementary data, Fig. S1). 
PGlyRP3 gene overexpression resulted in significant inhibition of the gene 
expression of IL-8 to 0.45±0.06, 0.66±0.04, IL-12p35 to 0.66±0.09, 0.76±0.07 
and TNF-α to 0.62±0.09, 0.63±0.08, 48 and 72 hrs post-transfection, 
respectively in Caco-2 cells, when compared with control cells that were 
transfected with the empty vector only (p< 0.005) (Fig. 5A).  
Two siRNA sequences specifically targeting PGlyRP3 were mixed and 
transiently transfected into Caco-2 cells. The PGlyRP3 gene knockdown was 
investigated 48 and 72h post-transfection by quantitative RT-PCR and Western 
blotting (supplementary data, Fig. S1). Specificity of gene silencing was 
confirmed, since transfection of a non-targeting, control siRNA sequence 
(siNEG) did not affect PGlyRP3 expression. The IL-8, IL-12p35 and TNF-α 
gene expressions were significantly increased in the siPGlyRP3 cells (Fig. 5B). 
1.24±0.05, 1.61±0.11 and 2.30±0.16-folds, respectively, after 48 h post 
silencing and 1.32±0.08, 1.75±0.31 and 1.65±0.16, respectively, after 72 h. In 
parallel experiments, siNEG sequence had no effect on IL-8, IL-12p35 and 
TNF-α gene expression. 
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Figure 4. Differential effects of FFA on cytokine gene expressions: Caco-2 
cells were incubated with 100 µM of different FFA. After 24 hrs of incubation, 
mRNA expression of IL-8 (A), IL-12p35 (B) and TNF-α(C) were analyzed by 
quantitative RT-PCR which was performed using SYBR Green. Data are 
expressed as mean ± SEM of n=4 experiments, * denotes significant difference 
from the non-treated control value. 
 
Chapter II 
 
 
36 
 
Figure 5. PGlyRP3 down regulates inflammatory cytokines expression in 
Caco-2 cells: Caco-2 cells were transfected with pCAGGS empty control 
vector or PGlyRP3 overexpression plasmid for 48 and 72 hrs (A) , or control 
negative siRNA or PGlyRP3 siRNA for 48 and 72 hrs (B). mRNA expression 
of IL-8, IL-12p35,TNF-α were analyzed by quantitative RT-PCR which was 
performed using SYBR Green. Data is expressed as relative mRNA 
accumulation corrected to β-actin mRNA as internal standard. The shown data 
is averages of 6 separate experiments performed in duplicates. Statistical 
analysis: * denotes p<0.05 in comparison to the corresponding control. 
 
 
FFA that upregulate PGlyRP3 inhibit cytokine gene expression 
The assumption that FFA regulate IL-8, IL-12p35 and TNF-α expression 
through PGlyRP3 was confirmed by incubating Caco-2 cells for 24 hrs with 100 
µM of oleic or palmitic acids after PGlyRP3-silencing and over-expression. 
Oleic acid which has been shown to induce the PGlyRP3 gene expression (Fig. 
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3B) and at the same time inhibit IL-8, IL-12p35 and TNF-α gene expressions 
(Fig. 4), significantly increased the gene expression of the tested cytokines (Fig. 
6A, left panel) and also protein expression of IL-12 (Fig. 6A, right panel) when 
added to the PGlyRP3-silenced Caco-2 cells. On the other side, incubation of 
PGlyRP3-overexpressing cells with this FFA enhanced the anti-inflammatory 
effect through inhibiting the gene expression of the tested cytokines (Fig. 6A, 
left panel) and also the protein secretion of IL-12 (Fig. 6A, right panel). In 
contrast, all cytokine gene expressions (Fig. 6B, left panel) and IL-12 protein 
secretion (Fig. 6B, right panel) were significantly increased in both PGlyRP3-
silenced and PGlyRP3-over-expressing Caco-2 cells after  incubation with 
palmitic acid, which has been previously shown to induce both PGlyRP3 and 
cytokines expression. Thus, palmitic acid enhanced the cytokine gene 
expression independent of the anti-inflammatory role of PGlyRP3. 
 
PGlyRP3 anti-inflammatory role includes the negative regulation of 
NF-κB pathway 
PPAR ligands have been reported to exert anti-inflammatory activities in 
different cells types by antagonizing the transcriptional activity of NF-κB 
through mechanisms that involve the induction of IκB-α expression and decay 
of COX-2 expression (24, 25). Therefore, we assumed that PGlyRP3 exerts its 
anti-inflammatory actions through a negative regulation of NF-κB pathway.  
Incubation of Caco-2 cells with the PPARγ ligands (GW1929, or oleic 
acid) induced the IκB-α and inhibited NF-κB and COX-2 gene expressions 
(supplementary data, Fig. S3). In the same line, PGlyRP3 over-expression 
caused an increased expression of IκB-α and a decreased expression of NF-κB 
and COX-2 genes (supplementary data, Fig. S3). On the other side, knocking 
down the PGlyRP3 and palmitic acid suppressed the gene expression of IκB-α 
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and induce the gene expression of NF-κB and COX-2 (supplementary data, Fig. 
S3). However, incubation of PGlyRP3-silenced cells with PPARγ agonist 
restored the IκB-α, NF-κB and COX-2 expression levels to the control value 
(supplementary data, Fig. S3). This indicates that PPARγ’s anti-inflammatory 
role is mediated via PGlyRP3-dependent and independent pathways. 
To further examine the NF-κB signalling pathway in Caco-2 cells, we 
investigated the effect of PGlyRP3 on the activation state of NF-κB in Caco-2 
cells by TransAm technique and Western blotting. Since NF-κB activation is 
accompanied by its translocation to the nucleus, we compared levels of NF-κB 
found in nuclear extracts from Caco-2 cells transfected with PGlyRP3 plasmid 
or PGlyRP3-silencing plasmid. Furthermore, we determined the NF-κB 
activation after incubation of Caco-2 cells with PPARγ agonist, oleic or palmitic 
acids. We found that PGlyRP3-silencing or palmitic acid-treatment induced the 
translocation of NF-κB into the nucleus (Fig. 7A,B,C), while PGlyRP3 over-
expression, PPARγ agonist and oleic acid suppressed the NF-κB translocation.  
Taken together, these results indicate that PGlyRP3 up-regulates the 
expression of IκB-α gene, down-regulates NF-κB and COX-2 genes expressions 
and inhibits the NF-κB nuclear localization. The present results suggest that the 
anti-inflammatory role of PGlyRP3 is exerted through the NF-κB pathway (Fig. 
7D).  
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Figure 6. FFA regulate cytokine gene expression through PGlyRP3: Caco-2 
cells were transfected with PGlyRP3 expression plasmid or with PGlyRP3 
siRNA for 24 hrs and treated with oleic (A) or palmitic acids (B). After 24 hrs 
incubation, mRNA expression of IL-8, IL-12p35, TNF-α were analyzed by 
quantitative PCR analysis which was performed using SYBR Green and IL-12 
secretion was analyzed by ELISA (A and B right panel). The shown data are 
averages of 6 separate experiments performed in duplicates. Statistical 
analysis: a, significantly different from the control non-treated; b, significantly 
different from the corresponding PGlyRP3 over-expression values; c, 
significantly different from the corresponding PGlyRP3 silencing values. 
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Figure 7. A negative regulation of NF-κB pathway is involved in the anti-
inflammatory PGlyRP3 role: Caco-2 cells were incubated with oleic or 
palmitic acids (A), GW1929 (B) or transfected with PGlyRP3 plasmid or 
siRNA (C). Nuclear and cytoplasmic proteins were extracted from these cells. 
NF-κB (p65) activation was assayed by TransAm (A, B and C upper panel). 
Western blot analysis was applied to Caco-2 nuclear (N) and cytoplasmic (C) 
extracts of the same treatments (A, B and C lower panel). Data is presented as 
mean ± SEM of n = 4 experiments performed in duplicates. Statistical analysis: 
*, significantly different from the control. (D) Proposed sequence of events that 
lead to suppression of inflammation by PPARγ-induced PGlyRP3 expression.  
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DISCUSSION  
This study was designed to investigate the immunomodulatory role of 
FFA through the regulation of PGlyRPs. We focused on PGlyRP3 because of 
the observation that Caco-2 cells expresse only the PGlyRP3 gene (Fig. 1). 
Previous studies have shown that PGlyRP3 gene is widely expressed in human 
tissues including skin, eyes, salivary glands, throat, tongue, esophagus, stomach 
and intestine (20). Our results demonstrate that PGlyRP3 modulate 
inflammatory cytokine production in enterocytes through PPARγ and its 
lipophilic ligands, which enhance induction of PGlyRP3 in Caco-2. The results 
also show an anti-inflammatory role of PGlyRP3 gene in the intestinal cells. 
The present results demonstrate the regulation of PGlyRP3 gene 
expression in Caco-2 cells by PPARγ-RXRα complex. First, in silico analysis 
demonstrated that there is a PPARγ-responsive element (PPRE) in the distal 
region of the PGlyRP3 gene promoter. This was verified by EMSA showing 
that PPARγ and PPARγ-RXRα complex bind to the distal PGlyRP3 promoter 
region (Fig. 2). Second, this PPARγ-responsive element on the PGlyRP3 gene 
promoter is functional: PGlyRP3 expression was enhanced by GW1929 
(PPARγ agonist) (Fig. 3A) and different FFAs (Fig. 3B), which are ligands of 
PPARγ. Third, the effect of FFAs on PGlyRP3 gene expressions was abolished 
by treatment with the PPARγ antagonist GW9662 (Fig. 3C). Taken together, the 
present results prove the modulation of PGlyRP3 gene expression by PPARγ-
RXRα complex. This modulation represents a novel regulatory pathway of the 
PGlyRP3 gene.  
It is known that up-regulation of PGlyRP mRNAs expression induced by 
bacterial cell surface components is mediated through NF-κB. Suppression of 
NF-κB activation prevented the induction of PGlyRPs gene expression induced 
by PAMPs (7, 26). On the other hand, it was also reported that ligand-activated 
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PPARγ down-regulates NF-κB transcription (27) and TLR4 protein and mRNA 
expressions (28). We therefore have expected that activation of PPARγ will 
downregulate NF-κB, which in turn down-regulates PGlyRP3 gene expression. 
The present results demonstrate that PGlyRP3 is, in contrast to our expectation, 
up-regulated by a PPARγ agonist and some PPARγ ligands. This up-regulation 
seems to be due to the direct binding between PPARγ and its PPRE in the 
promoter region of PGlyRP3 gene, rather than being mediated through NF-κB.  
The induction of PGlyRP3 gene expression and the dietary FFA that 
induce PGlyRP3 gene expression modulate the expression and production of 
some inflammatory cytokines in Caco-2 cells. The induction of PGlyRP3 gene 
expression, by FFA (Fig. 4, 6) or by over-expression (Fig. 5A, 6), inhibits, 
while suppression of its expression, by silencing, induces IL-8, IL-12p35 and 
TNF-α expression (Fig. 5B, 6). These results suggest that mammalian PGlyRP3 
has anti-inflammatory properties.  
The modulation of cytokines by FFA was also reported. The anti-
inflammatory effects of dietary oleic acid (29) and n-3-PUFAs (30) has been 
suggested to be mediated through the inhibition of TLR-induced signaling 
pathways, and the possibility that both the beneficial and detrimental effects of 
different dietary FFA may in part be mediated through the modulation of TLRs 
(31) or NODs (32). Activation of TLR or NODs synergistically initiates a 
signaling pathway leading to the activation of NF-κB (33, 34). In fact, 
activation of TLR and NOD pathways lead to activation of inflammatory 
pathways. NF-κB turns on many cytokine and chemokine genes (31), which 
mostly contain binding motifs for NF-κB in their promoter regions (35). Thus, 
palmitate increased, whereas poly-unsaturated FFA inhibited IL-8 gene 
expression and secretion through mechanisms involving activation of NF-κB in 
colonic epithelial cells (36). The present results demonstrate that PGlyRP3 
exerts a direct anti-inflammatory role, by inhibiting the studied pro-
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inflammatory cytokines through a mechanism including the suppression of NF-
κB pathway (Fig. 7).   
On the other side, the activation of PPARγ by certain polyunsaturated 
FFA (37), phytanate (31) and butyrate (38) has been reported. It is also known 
that PPARγ agonists inhibit the production of inflammatory cytokines (39, 40). 
This is confirmed in our present study in which the PPARγ agonist inhibited IL-
8, IL-12p35 and TNF-α genes expression in Caco-2 cells (supplementary data, 
Fig. S4). In addition, Clare’s group found that Cis-9, trans-11-conjugated 
linoleic acid but not trans-vaccenic acid reduced the gene expression of TNF-α, 
IL-12p35 and IL-6 and the concentration of IL-12p10 in Caco-2 cells via NF-κB 
and/or PPARγ-dependent mechanism (41). It was showed that PPAR ligands 
exert their anti-inflammatory activities in different cells by antagonizing the 
transcriptional activity of NF-κB by the induction of IκB-α expression (23). In 
addition, treatment with the PPARγ ligands promotes the decay of COX-2 
expression. Induction of IκB-α and the subsequent inhibition of NF-κB have 
been reported to mediate the inhibition of adhesion molecules and COX-2 
expression (25). However, the mechanism by which PPARγ up-regulates the 
IκB-α induction is not fully understood. Our study demonstrates that PPARγ 
exerts its anti-inflammatory effect due to a direct binding to and modulation of 
the expression and activity of the PGlyRP3 gene, which in turn activates IκB-α 
and inhibits the NF-κB translocation into the nucleus. In this context, it could be 
shown that FFA of food or microbial origin could modulate the immunological 
PGlyRP3 gene through PPARγ. The induction of PGlyRP3 gene was sufficient 
to up-regulate IκB-α and down-regulate the transcription of NF-κB, COX-2 and 
different cytokines. 
In summary, our results suggest that PGlyRP3 protein is involved in 
inhibiting inflammation and possibly immunotolerance, and is modulated by 
Chapter II 
 
 
44 
non-microbial as well as by microbial lipophilic ligands of PPARγ. These 
results demonstrate a differential modulation of IL-8, IL-12 and TNF-α 
expression by PPARγ and its lipophilic ligands (FFA) in Caco-2 cells mediated 
through binding of PPARγ to PGlyRP3 gene promoter, which leads to PGlyRP3 
transcription.  
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SUPPLEMENTARY DATA 
 
 
 
 
 
FIG. S1.  Evidence of PGlyRP3 silencing / over-expression in Caco-2 cells: 
Cells were transfected with a mixture of 2 siRNA, silencing negative, empty 
vector or PGlyRP3 plasmid. RNA was isolated after either 48 or 72 hrs. A and 
B) Quantitative PCR analysis of PGlyRP3 gene expression after silencing (si) 
and overexpresion (OE). Statistical analysis: * denotes difference from control; 
# denotes difference from the 48 hr-value. C) Western blot analysis of 
PGlyRP3 protein expression after silencing and over-expression. 
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Fig. S2. Fatty acids regulate cytokine gene expression through PGlyRP3: 
Caco-2 cells were transfected with PGlyRP3 expression plasmid or with 
PGlyRP3 siRNA for 24 hrs and treated with one of the following fatty acids: 
(A) phytanic, (B) c15, (C) EPA, (D) linoleic  acids. After 24 hrs incubation, 
mRNA expression of IL-8, IL-12p35,TNF-α were analyzed by quantitative RT-
PCR analysis which was performed using SYBR Green. Results are expressed 
as relative mRNA to β-actin mRNA as internal standard. The shown data are 
averages of 6 separate experiments performed in duplicates. Statistical 
analysis: a, significantly different from the control non-treated; b, significantly 
different from the corresponding PGlyRP3 over-expression values; c, 
significantly different from the corresponding PGlyRP3 silencing values. 
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Fig. S3. A negative regulation of NF-κB pathway is involved in the anti-
inflammatory PGlyRP3 role: Caco-2 cells were incubated with GW1929, oleic 
or palmitic acids, or transfected with PGlyRP3 plasmid or siRNA. mRNA was 
analysed for the gene expression of (A) IκB-α, (B) NF-κB and (C) COX-2 
quantitatively by RT-PCR.  Data is presented as mean ± SEM of n = 4 
experiments performed in duplicates. Statistical analysis: a, significantly 
different from the non-treated control; b, significantly higher than the PPARγ 
value; c, significantly lower than the silencing value. 
Chapter II 
 
 
52 
 
 
Fig. S4. PPARγ inhibit cytokines expression: Caco-2 cells were cultured with 
or without 10μM of the PPARγ agonist GW 1929 for 24 hrs. After incubation, 
total RNA was extracted and reverse transcribed to cDNA, then the expression 
of IL-8, IL-12p35 and TNF-α were analyzed by quantitative RT-PCR using 
SYBR Green assays. Results are expressed as relative to β-Actin mRNA as 
internal standard. The shown data are averages of 4 separate experiments 
performed in duplicates. Statistical analysis: * denotes p<0.003 in comparison 
to the control cultures. 
 
 
 
 
 
 
 
 
Table 1. Nucleotide sequences of studied  genes for RT-PCR  
 
Gene 
Accession 
No. 
Sense primer Antisense primer 
Product 
size (bp) 
PGlyRP3 NM_052891 5’-ACCCTCAACATCCAGTGATGC-3’ 5’-ATCCAACCCCTTCATACACGC-3’ 273 
IL-8 NM_000584 5’- GTGCAGTTTTGCCAAGGAGTG -3’ 5’- ACTTCTCCACAACCCTCTGC -3’ 215 
IL-12p35 NM_000882 5’- TTGTGGCTACCCTGGTCCT-3’ 5’- AGAGTTTGTCTGGCCTTCTGG -3’ 151 
TNF-α NM_000594 5’- TCAACCTCCTCTCTGCCATC -3’ 5’- CCAAAGTAGACCTGCCCAGA -3’ 187 
IκB-α NM_020529 5’- CTCCATCCTGAAGGCTACCA -3’ 5’- CCCCACACTTCAACAGGAGT -3’ 203 
NF-κB1 NM_003998 5’- ACTGTGAGGATGGGATCTGC -3’ 5’- GCACCAAGAGTCCAGGATTA -3’ 165 
COX-2 NM_000963 5’- CCACCCGCAGTACAGAAAGT -3’ 5’- CAGGATACAGCTCCACAGCA -3’ 196 
β- Actin NM_001101 5’- GATATCGCTGCGCTCGTC-3’ 5’-TCCATATCGTCCCAGTTGG-3’ 239 
Oligonucleotide sequences for EMSA 
PGlyRP3 NM_052891 5’-TCTCATAGGTCATTGTGAGACTACTTAGTG-3’ 5’-ACTAAGTAGTCTCACAATGACCTATGAGA-3’  
Oligonucleotide sequences for PGlyRP3 gene cloning 
EcoRIPGlyRP3  5’-CTGGAATTCATGGGGACGCTGCCATGG-3’  1044 
Xhol-PGlyRP3   5’-CAGCTCGAGTCAGTGCTTGAAATGAGG-3’  
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ABSTRACT 
Prebiotic oligosaccharides modulate the intestinal microbiota and 
beneficially affect the human body through reducing the intestinal 
inflammation. This immunomodulatory effect was assumed to be bacterial in 
origin. However, some observations suggest that oligosaccharides may exert an 
anti-inflammatory effect per se. We hypothesize that oligosaccharides affect the 
intestinal immunity via activation of PGlyRP3, which reduces the expression of 
pro-inflammatory cytokines. 
The results showed that the oligosaccharides α 3-sialyllactose and the 
fructo-oligosaccharide (Raftilose p95) have anti-inflammatory potency through 
reduction of IL-12 secretion in Caco-2 cells and gene expression of IL-12 p35,  
IL-8 and TNF-α. They also reduced the gene expression and nuclear 
translocation of NF-kB. Both oligosaccharides induced dose and time-
dependently the production of PGlyRP3, whose silencing abolished the anti-
inflammatory role of both oligosaccharides. Incubation of Caco-2 cells with 
both oligosaccharides induced PPARγ. PPARγ antagonism inhibited the 
oligosaccharide-induced PGlyRP3 production and the anti-inflammatory effect. 
We conclude that oligosaccharides may exert an anti-inflammatory effect 
by inducing the nuclear receptor PPARγ, which regulates the anti-inflammatory 
PGlyRP3. 
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INTRODUCTION 
Prebiotics are non-digestible food components that beneficially affect the 
human body through modulation of the intestinal microbiota by selectively 
stimulating the growth and/or activity of some bacterial species in the colon (1). 
They are complex carbohydrates with the fructooligosaccharides (FOS) and the 
mannooligosaccharides (MOS), which are the most frequently encountered 
commercial forms. These oligosaccharides contain three-to-ten monosaccharide 
residues covalently linked through glycosidic bonds. Neutral oligosaccharides 
contain no charged carbohydrate residues, while acidic oligosaccharides contain 
one or more negatively charged COOH-containing residues such as N-
acetylneuraminic acid (sialic acid) (2). Oligosaccharides are present at a high 
concentration in human milk. About 80 different oligosaccharides with will 
defined chemical structures have been isolated from human milk (3). In bovine 
milk, oligosaccharides are present in smaller amounts. In bovine colostrum the 
concentrations are considerably higher than in bovine milk. The most abundant 
acidic oligosaccharides in bovine colostrum are 3-sialyllactose, sialyllactose 
amine, 6-sialyllactose and disialyllactose (4). Also in plants (vegetables, cereals, 
roots, and fruits) prebiotic oligosaccharides were found, where they serve as 
storage carbohydrates. They consist of mixtures of fructose moieties linked by 
β-(2→1)-glycosidic bonds with a terminal glucose unit. These are neither 
digestible nor absorbed in the stomach and small intestine, and reach the colon, 
where they are fermented by the microbiota (5). Raftilose P95 is composed of 
95% FOS, it is the prebiotic inulin enriched with oligofructose (5).  
The immune system highly depends on a satisfactory supply of nutrients 
to function (6). Few studies have considered the immunomodulatory effects of 
oligosaccharides in humans and experimental animal models. The daily 
administration of different oligosaccharides significantly reduced damage 
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associated with Crohn's disease, ulcerative colitis and experimental colitis in 
rats (7-10). It was also reported that the acidic oligosaccharide increased the 
secretion of the interferon-gamma in CD3+ CD4+ and CD3+ CD8+ cells and 
the IL-13 secretion in CD3+ CD8+ cells (11). Moreover, human and plant milk-
derived oligosaccharides regulate the secretion of some in cord blood derived T 
cells in vitro (11). An immunomodulatory effect of bovine colostrum has been 
reported on the gut-associated lymphoid tissue (GALT), which responded by 
producing both Th1 pro-inflammatory cytokines (IL-2, IFN-γ and IL-12) and 
Th2 anti-inflammatory cytokines (IL-4 and IL10). This balance between Th1 
and Th2 cytokines production protected the weaned piglets from both allergic 
and infectious diseases (12). It was found that, the FOS supplementation affect 
the mucosal dendritic cell (DC) function by increasing the faecal bifidobacteria 
concentrations which, increased the percentage of lamina propria DC releasing 
IL-10 and decreased Crohn’s disease activity. This in vivo immunomodulatory 
effect was reported to be dependent on the bifidogenic effect of FOS acting via 
TLRs or other pattern recognition receptors (9, 13). However, the anti-
inflammatory events such as triggering IL-10 production also occur in vitro (9). 
This suggests that oligosaccharides render this effect per se (9). In addition, 
there is evidence that oligosaccharides can interact with the immune system not 
only via the intestinal flora but also by direct interaction with immune cells (14)  
PGlyRPs are a novel family of pattern recognition molecules (PRMs) that 
are highly conserved from insects to mammals (15, 16). Mammals have four 
PGlyRPs named PGlyRP1, 2, 3, and 4 (15,16). The family members show 
selective and differential expression; PGlyRP1 is highly expressed in bone 
marrow, PGlyRP2 in the liver, and PGlyRP3 and 4 in the oesophagus and 
elementary canal (17). Their distinct expression patterns suggest that each may 
play a unique role in host defence. Our previous study (18) showed that the only 
PGlyRP3 is expressed in Caco-2 cells. So far, there is no information available 
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whether the immunomodulation of oligosaccharides takes place through 
recognition pattern receptors such as PGlyRPs. Our previous results showed 
that PGlyRP3 mediates anti-inflammatory effects through NF-κB pathway 
suppression (18). We hypothesize that oligosaccharides can initiate an anti-
inflammatory response even in the absence of intestinal bacteria, through a 
direct activation of PGlyRP3. To test this hypothesis, we exposed the intestinal 
Caco-2 cells in vitro to 2 different oligosaccharides and quantified the effect on 
PGlyRP3 expression and tried to elucidate the role of this pattern recognition 
receptor. 
 
MATERIAL AND METHODS 
 
Cell culture 
Caco-2 cells were obtained from the American Type Culture Collection 
Company (ATCC). Cells between passages 10-50 were grown in 75 cm² culture 
flasks at 37°C and 5% CO2 using Minimum Essential Medium (MEM + 
GlutaMAX
TM
, Invitrogen, Karlsruhe, Germany) supplemented with 20% fetal 
calf serum, 100 IU penicillin/ml and 1% non-essential amino acids. For 
investigating the effects of oligosaccharides, cells were cultured in 6 well plates 
until reaching 7 days post confluency. Cells were fasted for 2 hours in 
Minimum Essential Medium (MEM + GlutaMAX
TM
) without any 
supplementations before the experimental incubations. For over-expression and 
RNA-silencing experiments, cells were cultured in 24-well plates until reaching 
80-100% confluence. 
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Preparation of oligosaccharides and incubation regimes 
α3-sialyllactose was provided by GALAB Technologies (Geesthacht, 
Germany), while Raftilose P95 was obtained from Orafti (Tienen, Belgium). 
Stock solutions were prepared by dissolving oligosaccharides in MEM + 
GlutaMAX
TM
. Fasted cells were incubated for 24 h with different 
concentrations of α3-sialyllactose or Raftilose P95 or for 3, 6, 12, 24 hours with 
a concentration of 50 mg/L or 50 g/L of α3-sialyllactose and Raftilose P95, 
respectively. Control incubations were supplemented with the MEM + 
GlutaMAX
TM
. 
 
RNA isolation, cDNA synthesis, and quantitative real time PCR 
analysis  
All quantitative RT-PCR analyses were performed on an Applied 
Biosystems ABI Prism 7000 system using cDNA samples corresponding to 20 
ng RNA. Quantitative analysis of PGlyRP3 gene expression was undertaken by 
using TaqMan gene expression assay in a 30 µl reaction volume with universal 
PCR master mix and TaqMan MGB probe (No. Hs 01074825_ml, Applied 
Biosystems, Cambridge, UK). Analyses of all other studied genes were 
performed using SYBR Green (Power SYBR green Mastermix, Applied 
Biosystems). All studied genes were quantified within the same cDNA samples. 
A dissociation curve was performed for each product to assure the absence of 
primer dimers or unspecific products. Primers used in the present study are 
listed in Table 1.  
To normalize expression data, β-actin was used as an internal control 
gene. Data are presented as fold difference from control, considering the control 
values as 1. 
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Table 1. Nucleotide sequences of primers for the genes studied by using RT-
PCR. 
 
Gene Accession 
No. 
Sense primer Antisense primer Product 
size (bp) 
 
PGlyRP3 
 
NM_052891 
 
5’-ACCCTCAACATCCAGTGATGC-3’ 
 
5’-ATCCAACCCCTTCATACACGC-3’ 
 
273 
IL-8 NM_000584 5’- GTGCAGTTTTGCCAAGGAGTG -3’ 5’- ACTTCTCCACAACCCTCTGC -3’ 215 
IL-12p35 NM_000882 5’- TTGTGGCTACCCTGGTCCT-3’ 5’- AGAGTTTGTCTGGCCTTCTGG -3’ 151 
TNF-α NM_000594 5’- TCAACCTCCTCTCTGCCATC -3’ 5’- CCAAAGTAGACCTGCCCAGA -3’ 187 
NF-κB1 NM_003998 5’- ACTGTGAGGATGGGATCTGC -3’ 5’- GCACCAAGAGTCCAGGATTA -3’ 165 
PPARγ NM_013124     5’- TGGGAGATCCTCCTGTTGAC-3’ 5’- GGAGCAGAAATGCTGGAGAA-3’ 214 
β- Actin NM_001101 5’- GATATCGCTGCGCTCGTC-3’ 5’-TCCATATCGTCCCAGTTGG-3’ 239 
 
Oligonucleotide sequences for PGlyRP3 gene cloning 
 
EcoRIPGlyRP3  5’-CTGGAATTCATGGGGACGCTGCCATGG-3’  1044 
Xhol-PGlyRP3   5’-CAGCTCGAGTCAGTGCTTGAAATGAGG-3’  
 
 
Transfection of Caco-2 cells with PGlyRP3 overexpression plasmid 
RNA was isolated from human oesophagus (approved by the ethics 
committee of the Christian-Albrechts-University of Kiel “protocol A 120/05”) 
and using the designed primers (table 1), full-length cDNAs coding for 
PGlyRP3 was cloned. We designed oligonucleotide primers after testing the 
sequences for restriction enzymes (Xho1 and EcoR1) that neither cut within the 
PGlyRP3 nor the vector sequences. The PCR products were ligated into the 
pCAGGS vector (T4-Ligase Rapid-Kit, Fermentas, Karlsruhe, Germany), and 
clones with the proper full-length PGlyRP3 insert were selected and identified 
by restriction digestion and sequencing the inserts. The cloned PGlyRP3 was 
identical to the genomic sequences. 
Caco-2 cells were seeded in a 24-well plate at a density of 4x10
4
 cells per 
well in 1 ml of culture medium and transfections performed at 60–80% cell 
confluence. Prior to transfection, TurboFect (Fermentas) and MEM (Invitrogen) 
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were mixed and incubated at room temperature for 20 min. 100 ng DNA was 
added in a ratio of 3:1 (TurboFect in µl: DNA in ng) as recommended by the 
manufacturer. Control samples were treated similarly and transfected with the 
empty vector (pCAAGS). After 48 and 72 h post transfection, RNA was 
isolated and transferred into cDNA. PGlyRP3 gene over-expression was 
confirmed using quantitative RT-PCR and Western blot. 
 
Small interfering (si) RNA experiments 
Two siRNA sequences targeting PGlyRP3 (SiSelect siRNA no. s41580 
and s41581) and a non-targeting negative control sequence (SC 4390843) were 
purchased from Ambion (Applied Biosystems). Caco-2 cells were reverse 
transfected with siRNA using siPORT NeoFX Transfection Reagent (Ambion, 
Applied Biosystems). siRNA was prepared in Opti-MEM serum-free medium 
(Invitrogen) by mixing 2 µl of the transfection reagent with 5 nM siRNA, 
respectively, at room temperature for 10 min. Caco-2 cells (4x10
4
 cells per well) 
were transferred to a 24-well plate containing siRNA transfection reagent 
complexes, allowing transfection to occur during initial cell adherence. Medium 
was replaced after 24 h by medium containing 20% FCS (allowing cell 
recovery) and incubation continued for an additional 24 and 48 h then RNA was 
isolated and transferred into cDNA. PGlyRP3 gene knock-down was confirmed 
by quantitative RT-PCR and Western blot. 
 
TransAm assay for NF-κB nuclear localization  
Caco-2 cells were incubated with 50 mg/L of α3-sialyllactose or 50 g/L of 
Raftilose p95 for 6 h. Nuclear extracts were prepared using a nuclear extraction 
kit (Panomics, Affymetrix, Heidelberg, Germany) according to manufacturer’s 
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instructions. Nuclear localization of NF-κBwas quantified using Transcription 
Factor ELISA kit (TransAm) to detect activated p65 subunit of NF-κB as 
illustrated in the kit user manual (Panomics, Affymetrix).  
 
Protein extraction and Western blot analysis 
 The cell lysates were subjected to 12% SDS-PAGE and blotted onto 
PVDF transfer membranes. Membranes were blocked with a mixture of 2.5% 
BSA and 2.5% skimmed milk and incubated with mouse monoclonal anti-
human PGlyRP3 (1:200, AXXORA, Lörr, Germany) and rabbit polyclonal anti-
human GAPDH (1:500, Santa Cruz Biotechnology, Heidelberg, Germany). 
Immunoreactive bands were detected with HRP-conjugated secondary antibody. 
 
Interleukin 12 protein assay 
 The human total IL-12 in the supernatant obtained from Caco-2 cell 
cultures after each treatment was detected using an ELISA kit (Mabtech AB, 
Hamburg, Germany) according to the manufacturer's instructions. 
 
Statistical analyses 
All samples were measured in duplicates. Values were expressed as mean 
± SEM. with n ≥ 4 in all experiments and the p value was indicated in the 
Results section. Group statistical comparisons were performed by one-way 
analysis of variances followed by Mann-Whitney multi-range analysis as a post-
hoc test. For comparisons in dose and time curves, data was analyzed by 
ANOVA with repeated measures. Paired comparisons were performed by t-test, 
when application of ANOVA was not necessary. All analyses were performed 
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using Statgraphics plus software and differences among means were considered 
significant at P values < 0.05. 
 
 
RESULTS 
 
Inhibition of pro-inflammatory cytokines by oligosaccharides 
We measured the mRNA level of interleukins IL-12p35, IL-8 and tumor 
necrosis factor-α (TNF-α) by quantitative RT-PCR and IL-12 protein secretion 
by ELISA in Caco-2 cells treated with 50 mg/L of α3-sialyllactose or 50 g/L of 
Raftilose p95 for 6 h. Both oligosaccharides suppressed significantly (P<0.05) 
IL-12p35 to 53.0±1.3% and 62.0±5.0%; IL-8 to 54.0±1.5% and 56.5±2.7% and 
TNF-α expression to 55.0±1.0% and 38.0±1.1% of the control, respectively 
(Fig. 1a, c). ELISA measurement of IL-12 revealed also that both 
oligosaccharides inhibited the protein secretion of IL-12 significantly (P<0.05) 
(Fig. 1b, d). α3-sialyllactose reduced this secretion from 59.4.0±2.7 to 18.4±0.6 
ng/ml, while Raftilose p95 decreased the secretion of IL-12 from 59.4.0±2.7 to 
35.0±2.1 ng/ml.  
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Figure 1. Inhibition of pro-inflammatory cytokine expression and NF-kB in 
intestinal Caco-2 cells by oligosaccharides: Caco-2 cells were incubated with 
50 mg/L of α3-sialyllactose (a, b) or 50 g/L of Raftilose p95 (c, d). After 6h 
incubation, total RNA was extracted and supernatants were collected. mRNA 
expression of IL-12p35, IL-8 and TNF-α  were analyzed by quantitative RT-PCR 
using SYBR Green (a, c). IL-12 protein secretion was measured by ELISA (b, 
d). (e) Relative NF-kB1 mRNA expression after treatment with the same 
oligosaccharides. (f) The NF-kB part P65 was estimated in nuclear extracts 
obtained from the treated cells at 450 OD. PCR results are expressed as relative 
to β-actin mRNA. Data are expressed as mean ± SEM of n=4 experiments. (*) 
denotes significant difference from the non-treated control value (t-test, p<0.05). 
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Dose and time-dependence of induction of PGlyRP3 by 
oligosaccharides  
Caco-2 Cells incubation for 24 h with various concentrations of α3-
sialyllactose or Raftilose p95 resulted in a dose-dependent induction of 
PGlyRP3 transcripts and proteins (Fig. 2). Increased expression of PGlyRP3 
mRNA (Fig. 2a) and increased amounts of protein (Fig. 2b) were observed 
when 50 mg/L of α3-sialyllactose was applied, while the relative PGlyRP3 
mRNA levels decreased when the concentration of α3-sialyllactose was higher 
than 50 mg/L. The incubation with Raftilose p95 resulted in a dose-dependent 
induction of PGlyRP3 mRNA (Fig. 2c) and protein (Fig. 2d) in the range of 
0.05 to 50 g/L. Both α3-sialyllactose and Raftilose p95 time-dependently 
influenced PGlyRP3 gene expression in Caco-2. The expression of PGlyRP3 
mRNA and protein were induced by α3-sialyllactose (Fig. 2e and f) or Raftilose 
p95 Fig. 2g and h) within the first 3h, and reached a peak after 6 h.  
 
Dependence of the anti-inflammatory effect of oligosaccharides on 
PGlyRP3 gene expression 
Incubation of Caco-2 cells for 6 h with 50 mg/L of α3-sialyllactose or 50 
g/L of Raftilose p95 inhibited cytokine gene expression (Fig.3). PGlyRP3-
silencing significantly increased the gene expression of IL-12p35, IL-8 and 
TNF-α  genes (Fig. 3a) as well as IL-12 protein secretion (Fig. 3b).  The 
inhibitory effect of oligosaccharides was associated with increased PGlyRP3 
gene and protein expressions (Fig. 3c and d). Despite PGlyRP3 silencing, 
treatment with the oligosaccharides could significantly reduce the pro-
inflammatory cytokines, when compared with that in PGlyRP3-silenced cells. 
This indicates that PGlyRP3 is not the only way of oligosaccharides to exert 
their anti-inflammatory action, and that both oligosaccharides and PGlyRP3 can 
reduce the cytokines independently from each other. 
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Figure. 2. Dose and time–dependence of induction of PGlyRP3 in the 
intestinal Caco-2 cells by oligosaccharides: Caco-2 cells were cultured with 
different concentrations of α3-sialyllactose (a, b), or Raftilose p95 (c, d) for 24 h, 
or cultured with 50 mg/L of α3-sialyllactose(e, f) or 50 g/L Raftilose p95 (g, h) 
for 0, 3, 6, 12 or 24 h. After incubation, total RNA was extracted and transcribed 
to cDNA, and then the expression of PGlyRP3 was assessed by quantitative RT-
PCR using TaqMan gene expression assays. Results are expressed as relative to 
β-actin mRNA as internal standard. Immunoblots represent PGlyRP3 protein of 
the same experiments. The shown data are averages of  separate experiments 
performed in duplicates. * denotes p<0.05 in comparison to the control cultures.  
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Figure. 3. Dependence of the anti-inflammatory effect of oligosaccharides 
on PGlyRP3 expression: Caco-2 cells were transfected with 5 nM PGlyRP3 
siRNA. After 24h the cells were treated with 50 mg/L of α3-sialyllactose or 50 
g/L of Raftilose p95. After 6h incubation, total RNA was extracted and 
supernatants were collected. a) mRNA expression of IL-12p35, IL-8 and TNF-α 
were analyzed by quantitative RT-PCR analysis. b) Protein secretion of IL-12 
was measured by ELISA. c) PGlyRP3 protein was assayed by Western blotting. 
d) mRNA expression of PGlyRP3 was analyzed by quantitative RT-PCR 
analysis using Taqman. The shown data are averages of 4 separate experiments 
performed in duplicates. Statistical analysis: a, significantly different from the 
control; b, significantly different from the corresponding PGlyRP3 silencing 
values (ANOVA followed by Mann-Whitney test). 
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PPARγ regulates PGlyRP3 expression and triggers the 
oligosaccharide-induced anti-inflammatory effects 
 
I) Oligosaccharides induce PPARγ expression 
In Caco-2 cells incubated with 50 mg/L of α3-sialyllactose or 50 g/L of 
Raftilose p95 for 6 h, the expression of PPARγ was increased to 200±6.6% and 
235±7.0% for α 3-Sialyllactose and Raftilose p95, respectively, compared to the 
control without oligosaccharide (Fig. 4a). This effect was confirmed on the 
protein level, as assessed by Western blot analysis (Fig. 4b). 
 
II) PPARγ antagonism abolished oligosaccharide-induced PGlyRP 
expression 
In Caco-2 cells treated with 10 µmol/L of the PPARγ antagonist 
(GW9662) for 24h and then with 50 mg/L of α3-sialyllactose or 50 g/L of 
Raftilose p95 for 6h, the oligosaccharides induced the gene expression of 
PGlyRP3 to 315±2.7% and 362±2.0% for α3-sialyllactose and Raftilose p95, 
respectively,  
compared to the control without oligosaccharides (Fig. 4c). This induction was 
abolished by the incubation with the PPARγ antagonist GW9662 (107±1.3 and 
95±1.1%, respectively, p<0.05). This effect was also observed on the PGlyRP3 
protein level  (Fig. 4d). 
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Figure 4. Oligosaccharides regulate PGlyRP3 expression and trigger anti-
inflammatory effects through PPARγ:. Caco-2 cells were cultured with and 
without 50 mg/L of α 3- Sialyllactose or 50 g/L of Raftilose p95 for 6 h. After 
incubations, total RNA was extracted and transcribed to cDNA, and then the 
expression of PPARγ was assessed qPCR using Sybr-green assay (a) and 
Western blot (b). Oligosaccahcarides-treated cells were incubated in the 
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presence or absence of the PPARγ inhibitor GW 9662. PGlyRP3 mRNA level 
was then assessed by qPCR using Taqman (c), PGlyRP3 protein was detected by 
Western blot (d), mRNA level of IL-12p35, IL-8 and TNF-α genes was assessed 
by qPCR using  Sybr-green (e), and IL-12 secretion was determined by ELISA 
in the supernatant (f). All qPCR results are expressed in relation to β-actin 
mRNA as internal standard. The shown data are averages of 6 separate 
experiments performed in duplicates. Statistical analyses: * denotes p<0.05 in 
comparison to the control cultures (t-test). a, significantly different from the 
control; b, significantly different from the corresponding PGlyRP3 silencing 
values (ANOVA followed by Mann-Whitney test). 
 
IV) PPARγ antagonism abolished the oligosaccharide-induced inhibition of 
cytokines expression 
In Caco-2 cells treated with 10 µmol/L of GW9662 for 24h and then with 
50 mg/L of α3-sialyllactose or 50 g/L of Raftilose p95 for 6 h the inhibition of 
gene expressions of IL-12p35, IL-8 and TNF-α  (Fig. 4e) and the secretion of 
IL-12 (Fig. 4f) by oligosaccharides was abolished by the incubation with the 
PPARγ antagonist GW9662. 
 
DISCUSSION 
This study was designed to investigate whether prebiotic oligosaccharides 
from plant and milk sources exert a direct anti-inflammatory effect in 
enterocytes and whether this is mediated by PGlyRPs. In the present study, we 
focused on PGlyRP3 because our previous results demonstrated that Caco-2 
cells express only PGlyRP3 (18). The present results demonstrate that the anti-
inflammatory role of α3-sialyllactose and Raftilose p95 in intestinal cells 
depends on the regulation of PPARγ and accordingly, PGlyRP3.  
Both applied oligosaccharides inhibited the expression of pro-
inflammatory cytokines and the nuclear translocation of NF-kB (Fig 1). The 
modulation of cytokines by oligosaccharides was previously observed in in vivo 
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studies and in vitro in lymphocytes (10, 12, 13). Also, our previous results 
demonstrated that PGlyRP3 exerts a direct anti-inflammatory role by inhibiting 
IL-8, IL-12 and TNF-α pro-inflammatory cytokines through a mechanism 
including the suppression of NF-κB pathway (18). In the present study, we 
found that PGlyRP3 expression was enhanced by both applied oligosaccharides 
and this induction was dose- and time- dependent (Fig. 2). The induction of 
PGlyRP3 gene expression by oligosaccharides, similar to its overexpression, 
inhibited IL-8, IL-12 and TNF-α expression. On the other hand, the anti-
inflammatory effect of oligosaccharides was masked by PGlyRP3 silencing (Fig 
3a, b). Accordingly, this anti-inflammatory effect by oligosaccharides showed a 
dependence on PGlyRP3 expression (Fig 3c). Taken together, the results 
suggest that the in vitro anti-inflammatory effect of the oligosaccharides α3-
sialyllactose and Raftilose p95 are triggered through induction of the anti-
inflammatory PGlyRP3 pathway. 
The modulation of cytokines by oligosaccharides through bifidobacteria 
was previously reported (9-12). Oligosaccharides were also reported to initiate 
some immunological events through interaction with TLRs, such as increasing 
TLR2 and/or TLR4 expression following daily FOS supplementation (9). It is 
known that oligosaccharides are fermented in the colon by intestinal microbial 
metabolic activity to short-chain fatty acids (SCFA) (19-22), which may have 
anti-inflammatory effect through activation of transcription factors. However, in 
the absence of microbiota and fatty acids in in vitro experiments, the 
immunomodulatory effect of oligosaccharides should be due to a direct 
signaling initiated by the oligosaccharides themselves (Fig. 1, 3, and 4). This 
was shown by Lindsay et al (9) in their dendritic cells (DC) model and by using 
enterocytes. This effect of oligosaccharides is suggested to be mediated through 
interaction with other recognition molecules than TLRs, since activation of 
TLR2 and 4 leads mostly to inflammatory response and does not explain, for 
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example, the increase of IL-10 in the DC-model (9). However, this recognition 
molecule may interact with some transcription factors as PPARγ and render its 
immunomodulatory effect. PPARγ is activated by certain polyunsaturated fatty 
acids (23), phytanic acid (24) and the short-chain butyric acid (25). In addition, 
PPARγ was reported to inhibit the production of inflammatory cytokines in 
different cell types by interfering with TLR4-dependant signaling pathway (26-
28). Our previous results demonstrated that PGlyRP3 is up-regulated by a 
PPARγ agonist and some free fatty acids, which are also PPARγ ligands. This 
up-regulation was due to a direct binding between PPARγ and its PPAR 
response elements PPRE on the promoter region of the PGlyRP3 gene. Thus, 
PPARγ also exerts its anti-inflammatory effect due to a direct binding to and 
modulation of the expression and activity of the PGlyRP3 gene, which in turn 
activates IκB-α and inhibits the NF-κB translocation into the nucleus and down-
regulate different pro-inflammatory cytokines (18). The applied 
oligosaccharides induced the expression of PPARγ (Fig 4) and induced an 
inhibition of pro-inflammatory cytokines. The oligosaccharides-induced 
suppression of pro-inflammatory cytokine expressions was abolished by the 
PPARγ antagonist GW9662 (Fig. 4). However, knocking down the PGlyRP3 
itself, increased the same pro-inflammatory cytokines with and without 
treatment with oligosaccharide (Fig. 3). These results suggest that the 
oligosaccharide mediated anti-inflammatory effect depends principally on 
PPARγ, which activation leads to PGlyRP3 induction. It seems that PPARγ has 
several ways to exert its anti-inflammatory role, and that activation of PGlyRP3 
is one of these ways.  
In summary, our results suggest that prebiotic oligosaccharides may have 
a direct anti-inflammatory effect. This effect seems to be PPARγ dependent and 
at least in part depend on PGlyRP3 expression. Furthermore, the results support 
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the idea that nutrients like dietary oligosaccharides may modulate the 
inflammatory state. 
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ABSTRACT 
 Intestinal epithelial cells produce cytokines in response to bacterial 
peptidoglycan (PGN), which is detected by several classes of pattern-
recognition receptors (PRRs) as peptidoglycan recognition proteins (PGlyRPs), 
Toll-like receptor 2 (TLR2) and NOD receptors. All types of PGlyRPs 
recognize bacterial peptidoglycan and function in antibacterial innate immunity. 
In this study, we investigated the role of PGlyRP3 in the response of intestinal 
epithelial cells (Caco-2) to PGN from pathogenic (Staphylococcus aureus), 
opportunistic pathogenic (Micrococcus luteus) and non-pathogenic (Bacillus 
subtilis and Lactobacillus rhamnosus GG) bacteria. All PGNs induced the 
proinflammatory cytokines IL-12p35, IL-8 and TNF-α and, time-dependently, 
PGlyRP3, at both the transcription and protein levels. In this context, no 
difference was observed between the effects of PGN obtained from different 
bacterial sources. The inflammatory response to PGN is mediated via the TLR2 
pathway, since blocking this pathway by inhibiting MyD88 reduced the 
expression of proinflammatory cytokines. In addition, PGlyRP3 overexpression 
suppressed, while PGlyRP3 knocking down enhanced the expression of PGN-
induced inflammatory cytokines. It is concluded that PGN stimulates 
inflammatory responses in the intestinal epithelia through activation of the TLR 
pathway. PGlyRP3 is also stimulated by PGN and has, in contrast to activation 
of the TLR pathway, an anti-inflammatory effect.  
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INTRODUCTION 
The innate immune system improves the early recognition of any 
invading microorganisms. Vertebrates and invertebrates have evolved pattern-
recognition receptors (PRRs) that sense the presence of pathogen-associated 
molecular patterns (PAMPs) such as lipopolysaccharide, nonmethylated CpG 
sequences, peptidoglycan (PGN), bacterial DNA and lipopolysaccharide (LPS), 
which are products of microbial metabolism and not produced by the host (1, 2). 
Bacteria stimulate the innate immune system of the host and the release of 
inflammatory molecules such as cytokines and chemokines (3, 4), which are the 
major cause of the various signs and symptoms that occur during bacterial 
infections, including fever, inflammation, and acute phase responses (5, 6). LPS 
is a well-known activator of the innate immune system in infections caused by 
Gram-negative bacteria (5), while infections with Gram-positive bacteria are 
sensed by PGN, the major component of the bacterial cell wall of Gram-positive 
bacteria (5, 6).  
PGN had been largely neglected for its capacity to induce immune 
responses. However, this has been changed recently with the discovery of 
several classes of PRRs required for PGN detection such as peptidoglycan 
recognition proteins (PGRPs), Toll-like receptor 2 (TLR2) and nucleotide-
binding oligomerization domain proteins (NODs) (7, 8). It was found that 
peptidoglycan from Gram-positive bacterial cell walls induce inflammation in 
rats and rabbits (9, 10). The immunomodulatory properties of peptidoglycan had 
been identified towards different in vitro models, for example: monocytes, 
macrophages (11, 12), neutrophils (13) and respiratory epithelial cells (14).  
Toll-like receptor 2 (TLR2) has been shown to recognize PGN, leading to 
the activation of the transcription factor NF-κB (15, 17), and immune 
stimulation (7). “This activation requires the signal transduction molecules 
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myeloid differentiation protein (MyD88), IL-1 receptor-associated kinase 
(IRAK), tumor necrosis factor (TNF) receptor-associated kinase 6 (TRAF6), 
NF-κB inducing kinase (NIK), and IκB kinase (IKK)” (18- 20). 
NOD1 and NOD2 are intracellular PRRs which, recognize the soluble 
PGN fragments in the cytoplasm (21, 22) and are involved also in innate 
immune defense responses through pathways that are independent of TLR (23, 
24). NOD1 is an upstream activator of NF-κB (25, 26). However, NOD2 was a 
susceptibility gene included in the Crohn's disease etiology , an inflammatory 
bowel disease controlled by both genetic and environmental factors (27, 28).  
PGRPs are a member of PRRs, they are highly conserved from insects to 
mammals. They recognize with high affinity bacterial peptidoglycan, and 
function in antibacterial immunity. Insects have many PGRPs with different 
functions, such as induction of antimicrobial peptide gene expression through 
activation of the TLR, IMD, and prophenoloxidase cascade pathways, induction 
of phagocytosis, hydrolysis of peptidoglycan, and down regulation of immune 
responses (22). The mammalian PGRP family is composed of four members. 
PGlyRP1, 3 and 4 are directly bactericidal (29), whereas PGlyRP2 has been 
reported to have amidase activity and hydrolyzes peptidoglycan (30, 31).         
In contrast to the insect PGRPs, little is known about the stimulatory role of 
mammalian PGRPs in intracellular signaling pathways. Nevertheless, few 
studies were conducted regarding the inflammatory role of PGRPs (32), while it 
is known that activation of TLR2 and NODs activates inflammatory pathways.  
We have recently detected the expression of PGlyRP3 in enterocytes 
(33). Whether it plays an inflammation promoting role in these cells is still 
unknown. The aim of our study was to investigate the response of PGlyRP3 in 
intestinal epithelial cells (Caco-2) to peptidoglycans isolated from different 
bacterial sources. For this purpose, we used PGN from non-pathogenic 
(Lactobacillus rhamnosus GG (LGG) and Bacillus subtilis), opportunistic 
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pathogenic (Micrococcus luteus) and pathogenic bacteria (Staphylococcus  
aureus). We identified an anti-inflammatory role of PGlyRP3, which is 
independent of TLR2.  
 
MATERIAL AND METHODS 
Cell culture  
Caco-2 cells were obtained from the American Type Culture Collection 
Company (ATCC). Cells between passages 10-50 were grown in 75 cm² culture 
flasks at 37°C and 5% CO2 using Minimum Essential Medium (MEM + 
Glutamax, Invitrogen, Karlsruhe, Germany) supplemented with 20% fetal calf 
serum, 100 IU penicillin/ml and 1% non-essential amino acids. For different 
experiments, cells were cultured in 6 well plates until reaching 7 days post 
confluence. Cells were fasted for 2 hours in Minimum Essential Medium (MEM 
+ Glutamax) without any supplementations before experimental intervention. 
For over-expression and RNA-silencing experiments, cells were cultured in 24-
well plates until reaching 80-100% confluence.  
 
Preparation of PGN and incubations 
PGN from B. subtilis, M. luteus and  S. aureus were purchased from 
(Sigma) PGN from LGG was prepared as previously described (34). Briefly, 
LGG was grown in deMan Rogosa Sharp (MRS) liquid medium for 48 h at 37 
℃ without shaking. The culture was quickly chilled in ice bath. Bacteria were 
harvested by centrifugation and washed several times with water. They were 
placed in a boiling water bath for 20 min followed by sonication. The 
suspension was centrifuged at 1 000 r/min for 15 min to sediment unbroken 
bacteria and the supernatant containing the cell walls was decanted. After 
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centrifugation at 10.000×g for 10 min, the pelleted cell walls were incubated in 
2% sodium dodecyl sulphate (SDS) for 30 min at 60 ℃. Covalently bound 
proteins were digested with 0.02% trypsin in 0.1 mol/l Tris-HCl buffer (pH 7.5) 
for 20 h at 37 ℃ after being washed four times with water and twice with 
dehydrated alcohol. The walls were washed several times with water, then 
lyophilized and resuspended in 10% trichloroacetic acid and stirred for 20 min 
at 60° C . PGN was concentrated by centrifugation (10 000×g, 20 min) and 
washed extensively with water. Stock solutions were prepared by dissolving 
PGN in MEM at a concentration of 1 mg/ml. 
Caco-2 cells were incubated for 3, 6, 12, 24 hours with one of the 
different PGN at a concentration of 10 µg/ml. 
 
Incubation with Myeloid differentiation 88 (MyD88) inhibitor  
 The MyD88 inhibitory peptide set was purchased from InvivoGene 
(France). Caco-2 cells were seeded in a 24-well plate. MyD88 inhibitory 
peptide or the control peptide (100 μM) were applied for 24 hrs according to the 
manufacturer’s instructions. 
 
Transfection of Caco-2 cells with PGlyRP3 plasmid 
RNA was isolated from human oesophagus (approved by the ethics 
committee of the Christian-Albrechts-University of Kiel “protocol A 120/05”) 
and using the designed primers (table 1), full-length cDNAs coding for 
PGlyRP3 was amplified. We designed oligonucleotide primers after testing the 
sequences for restriction enzymes (Xho1 and EcoR1) that neither cut within the 
PGlyRP3 nor the vector sequences. The PCR products were ligated into the 
pCAGGS vector (T4-Ligase Rapid-Kit (Fermentas, Karlsruhe, Germany), and 
clones with the proper full-length PGlyRP3 insert were selected and identified 
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by restriction digestion and sequencing the inserts. The cloned PGlyRP3 was 
identical to the sequence predicted from the genomic sequences. 
Caco-2 cells were seeded in a 24-well plate at a density of 4x10
4
 cells per 
well in 1 ml of culture medium and transfections performed at 60–80% cell 
confluence. Prior to transfection, TurboFect (Fermentas) and MEM (Invitrogen) 
were mixed and incubated at room temperature for 20 min. 100 ng DNA was 
added in a ratio of 3:1 (TurboFect in µl: DNA in ng) as recommended by the 
manufacturer. Control samples were treated similarly and transfected with the 
empty vector (pCAAGS). After 72 hrs post transfection, RNA was isolated and 
reverse transcribed into cDNA. PGlyRP3 gene over-expression was confirmed 
using quantitative RT-PCR and Western blot. 
 
Small interfering RNA experiments 
Two siRNA sequences targeting PGlyRP3 (Si Select si RNA no. s41580 
and s41581) and a non-targeting negative control sequence (SC 4390843) were 
purchased from Ambion (Applied Biosystems). Caco-2 cells were reverse 
transfected with siRNA using siPORT NeoFX Transfection Reagent (Ambion, 
Applied Biosystems). siRNA was prepared in Opti-MEM serum-free medium 
(Invitrogen) by mixing 2 µl of the transfection reagent with 5 nM siRNA, 
respectively, at room temperature for 10 min. Caco-2 cells (4x10
4
 cells per well) 
were transferred to a 24-well plate containing siRNA transfection reagent 
complexes, allowing transfection to occur during initial cell adherence. Medium 
was replaced after 24 hrs by medium containing 20% FCS (allowing cell 
recovery) and incubation continued for an additional 48 hrs then RNA was 
isolated and transferred into cDNA. PGlyRP3 gene knock-down was confirmed 
by quantitative RT-PCR and Western blot.  
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RNA Isolation, cDNA Synthesis, and Quantitative real time PCR 
analysis  
 Total RNA was isolated from Caco-2 cells using RNeasy kit (Qiagen, 
Hilden, Germany). To assure absence of genomic DNA, all RNA samples were 
treated with DNase-1, and multiple exon-spanning primers were used for PCR 
amplification. For reverse transcription, 1 µg of the total RNA was reverse 
transcribed to first strand complementary DNA in 25 µl reactions using the 
cDNA synthesis Taqman kit (Applied Biosystems). 
All quantitative RT-PCR analyses were performed on an Applied 
Biosystems ABI Prism 7000 system using cDNA samples corresponding to 20 
ng RNA. Quantitative analysis of PGlyRP3 gene expression was undertaken by 
using TaqMan gene expression assay in a 30 µl reaction with universal PCR 
master mix and TaqMan MGB probe (No. Hs 01074825_ml, Applied 
Biosystems, Cambridge, UK). To normalize expression data, β-actin was used 
as an internal control gene. Data are presented as fold difference from control, 
considering the control values as 1. 
Quantitative RT-PCR analyses of all other studied genes were performed using 
SYBR Green (Power SYBR green Mastermix, Applied Biosystems). All studied 
genes were quantified within the same cDNA samples. The thermal cycling 
program was 10 min at 95°C for enzyme activation and denaturation for 15 s at 
95°C, 60 s annealing at 60°C. A dissociation curve was performed for each 
product to assure the absence of primer dimers or unspecific products. Primers 
used in the present study are listed in Table 1.   
To normalize expression data, β-actin was used as an internal control 
gene. Data are presented as fold difference of control, considering the control 
values as 1. 
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Table 1. Nucleotide sequences of studied genes for RT-PCR and cloning. 
Gene 
Accession 
No. 
Sense primer Antisense primer 
Product 
size (bp) 
PGlyRP3 NM_052891 5’-ACCCTCAACATCCAGTGATGC-3’ 5’-ATCCAACCCCTTCATACACGC-3’ 273 
IL-8 NM_000584 5’- GTGCAGTTTTGCCAAGGAGTG -3’ 5’- ACTTCTCCACAACCCTCTGC -3’ 215 
IL-12p35 NM_000882 5’- TTGTGGCTACCCTGGTCCT-3’ 5’- AGAGTTTGTCTGGCCTTCTGG -3’ 151 
TNF-α NM_000594 5’- TCAACCTCCTCTCTGCCATC -3’ 5’- CCAAAGTAGACCTGCCCAGA -3’ 187 
β- Actin NM_001101 5’- GATATCGCTGCGCTCGTC-3’ 5’-TCCATATCGTCCCAGTTGG-3’ 239 
 
Oligonucleotide sequences for PGlyRP3 gene cloning 
 
EcoRIPGlyRP3  5’-CTGGAATTCATGGGGACGCTGCCATGG-3’  1044 
Xhol-PGlyRP3   5’-CAGCTCGAGTCAGTGCTTGAAATGAGG-3’  
 
 
 
Protein Extraction and Western blot analysis 
 The cell lysates were loaded into 12% SDS-PAGE and blotted onto 
PVDF transfer membranes. Membranes were blocked with a mixture of 2.5% 
BSA and 2.5% skimmed milk and incubated with mouse monoclonal anti-
human PGlyRP3 (1:200, AXXORA, Lörr, Germany) and rabbit polyclonal anti-
human GAPDH (1:500, Santa Cruz Biotechnology, Heidelberg, Germany). 
Immunoreactive bands were detected with horsereddish peroxidase(HRP)-
conjugated secondary antibodies. 
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Interleukin 12 protein assay 
 The human total IL-12 was detected using an ELISA kit (Mabtech AB, 
Hamburg, Germany) in the supernatant obtained from Caco-2 cell cultures after 
each treatment according to the manufacturer's instructions. 
 
Statistical analyses 
All samples were measured in duplicates. Values were expressed as mean 
± S.E.M. with n ≥ 4 in all experiments and p indicated in the Results section. 
Data were analyzed by paired t test or one way analysis of variance with 
repeated measures. All analyses were performed using Statgraphics plus 
software and differences among means were considered significant at P values 
< 0.05. 
  
RESULTS 
Different PGN induced PGlyRP3 expression 
PGlyRP3 gene expression was significantly induced after incubation of 
Caco-2 cells with 10 μg/ml PGN from B. subtilis, M. luteus, and S. aurues (p < 
0.05) for 3 hrs. This induction was reduced thereafter (Fig. 1A). After 
incubation of Caco-2 cells with PGN from LGG, a peak of PGlyRP3 gene 
expression was achieved after 12 hrs (Fig. 1A). Therefore, we chose the 3 hrs 
for B. subtilis, M. luteus, and S. aurues and 12 hrs for LGG as incubation time 
for the next experiments. Both B. subtilis and LGG PGNs induced PGlyRP3 
protein in Caco-2 cells along with its gene expression in a time-dependent 
course (Fig. 1B). 
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Figure 1. Time dependence of induction of PGlyRP3 by PGN :  
A) Quantitative PCR analysis for the expression of PGlyRP3 using cDNAs from 
Caco-2 cells treated with PGN of different bacterial sources: B. Subtilis, LGG, 
M. luteus and S. aureus. PCR was performed using PGlyRP3 TaqMan MGB 
probe. Data were normalized to the expression of β-actin. The data (mean ± 
SEM) are averages of 6 separate experiments performed in duplicates. * denotes 
significant differences from the untreated control value. B) PGlyRP3 protein 
production analysed by Western blotting. Cells were incubated for the indicated 
periods with 10 µg/ml of PGN from  B. Subtilis and LGG. Protein was then 
detected. 
 
PGN induce inflammatory cytokine 
 Incubation of Caco-2 cells with 10 μg/ml B. subtilis, M. luteus, S. aurues 
and LGG significantly (p<0.05) induced interleukin 12p35 (IL-12p35), 
interleukin 8 (IL-8) and tumor necrosis factor alpha (TNF-α) mRNA levels (Fig. 
PglyRP3 has anti-inflammatory role  in intestinal epithelial cells 
 
 
89 
2A). IL-12 protein concentration was detected by IL-12 ELISA in supernatants 
obtained from Caco-2 cell cultures after treatment with different PGNs. The 
protein concentrations of IL-12 were affected in the same manner like the 
mRNA levels (Fig. 2B). 
 
 
Figure 2. PGN induces inflammatory cytokine expression: Caco-2 cells were 
treated with 10 µg/ml of different bacterial source PGN. A) The mRNA 
expression of IL-12p35 , IL-8  and TNF-α was assessed by quantitative RT-PCR 
using SYBR Green. Results are related to β-actin mRNA as internal standard. B) 
IL-12 protein secretion was assessed by ELISA. Data are expressed as mean ± 
SEM of n=6 experiments, measured in duplicates, * denotes significant 
difference from the untreated control value. 
 
PGlyRP3 suppresses the PGN-induced inflammatory cytokines 
Caco-2 cells were transfected with a plasmid carrying the PGlyRP3 or 
siRNA against the same gene for 48 hrs. Cells were then incubated with 10 
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μg/ml PGN from B. subtilis, M. luteus, S. aurues for 3 hrs or PGN from LGG 
for 12 hrs. The results showed that PGlyRP3 overexpression reduced the LGG 
PGN-induced IL-12p35, IL-8 and TNF-α mRNA levels significantly to 1.12, 
1.30 and 1.46-folds compared to 2.01, 3.03 and 2.54-folds for the control. 
Similarly, PGlyRP3 overexpression reduced the B. subtilis PGN-induced IL-
12p35, IL-8 and TNF-α mRNA levels significantly to 1.34, 6.90 and 1.68-folds 
compared to 2.31, 10.44 and 3.40-folds for the controls. PGlyRP3 
overexpression reduced the M. luteus PGN-induced IL-12p35, IL-8 and TNF-α 
mRNA levels significantly to 1.90, 3.10 and 1.4-folds compared to 3.40, 5.14 
and 2.65-folds for the controls, and S. aureus PGN-induced IL-12p35, IL-8 and 
TNF-α mRNA levels significantly to 1.2, 2.29 and 1.4-folds compared to 3.53, 
6.14 and 2.97-folds for the controls (Fig. 3A). PGlyRP3 overexpression itself 
reduced the cytokine gene expression. IL-12p35, IL-8 and TNF-α mRNAs in 
PGlyRP3-overexpressing cells were 0.72, 0.59 and 0.49-folds respectively, 
compared to control cells, which were transfected with empty vector. PGlyRP3 
overexpression also reduced the PGN-induced IL-12 protein secretion to 
197.14, 314.72, 214.37 and 209.25 ng/ml compared to 345.29, 469.56, 389.53 
and 337.04 ng/ml for PGNs isolated from LGG, B. subtilis, M. luteus and S. 
aurues, respectively (Fig. 3B). These results indicate a modulation of the PGN 
mediated inflammatory effect by PGlyRP3.  
We found also that PGlyRP3 knocking increased significantly the IL-12p35, 
IL-8 and TNF-α gene expression to 1.94, 2.10 and 1.39-folds, respectively, 
compared with the control value of 1. Addition of  LGG, B. subtilis, M. luteus or 
S. aurues PGNs additively and severely increased the gene expression of IL-
12p35 to 2.90, 13.70, 9.12 and 14.4-folds , IL-8 to 3.33, 21.68, 20.26 and 23.05-
folds, and TNF-α to 3.25, 11.75, 4.28 and 7.3-folds, respectively (Fig. 3A), and 
the IL-12 protein expression to 1181.58, 13331.4, 1328.16 and 1266.99 ng/ml, 
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compared to 201.27 ng/ml for the group of PGlyRP3 silencing alone, and 
345.29, 469.56, 389.53 and 337.04 ng/ml for the PGN groups, respectively (Fig. 
3B). 
 
 
Figure 3. PGlyRP3 overexpression reduces the PGN–induced inflammatory 
cytokine: Caco-2 cells were transfected with PGlyRP3 plasmid or siRNA for 48 
hrs and then treated with one of the different PGN for additional 24 hrs. After 
the incubation, mRNA expression of IL-12p35, IL-8 and TNF-α were analyzed 
by quantitative PCR using SYBR Green (A). The protein secretion of IL-12 was 
analyzed by ELISA (B). The control values (untreated Caco-2 cells or Caco-2 
cells treated with empty plasmid or negative siRNA) are mentioned in Table 2. 
Data here are only compared to the PGN values. The shown data are averages of 
6 separate experiments performed in duplicates. Statistical analysis: ANOVA *= 
significantly different from the control Caco-2 cells treated with 10µg/ml PGN. 
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TLR but not PGlyRP3 pathway is involved in the inflammatory 
response to PGNs  
 PGN from LGG, B. subtilis, M. luteus, or S. aurues increased the mRNA 
expression of IL-12p35 to 3.03, 2.31, 5.14 and 6.14-folds; IL-8 to 1.8, 10.44, 
3.40 and 3.53-folds and TNF-α to 2.54, 3.40, 2.65 and 2.97-folds, respectively; 
and IL-12 secretion to 345.29, 469.56, 337.04 and 297.14 ng/ml respectively, 
compared to untreated controls 94,26 ng/ml (Fig. 2). As shown in figure 4, the 
mRNA level of all tested cytokines and IL-12 protein secretion were 
significantly reduced (p<0.05) after incubation of MyD88 inhibitory peptide-
treated Caco-2 cells with different PGNs. 
These results confirm that microbial PGNs act proinflammatory due to 
TLR pathway prevailing the anti-inflammatory PGlyRP3’s action. When 
PGlyRP3 expression is increased, the balance may be shifted towards lower 
inflammation.  
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Figure 4. Neutralization of the TLR-pathway by MyD88 inhibitor suppressed 
the PGN–induced inflammatory cytokine expression in Caco-2 cells: Caco-2 
cells were pre-treated  with 100 μM MyD88 inhibitory peptide or control 
peptide for 24 hrs then treated with 10 µg/ml PGN of different bacterial 
sources. A) mRNA expression of IL-12p35, IL-8 and TNF-α were analyzed 
by quantitative RT-PCR using SYBR Green. Results are expressed as relative 
mRNA to β-actin mRNA as internal standard. B) The secretion of IL-12 was 
analyzed by ELISA. The shown data is averages of 6 separate experiments 
performed in duplicates. Statistical analysis: * denotes p<0.05 in comparison 
to the PGN group which is considered here as a control group. Other control 
values (untreated Caco-2 cells or Caco-2 cells treated with control peptide) 
are mentioned in Table 2. 
CHPTER IV 
 
 
94 
Furthermore, as shown in Figure 5, IL-12p35, IL-8 and TNF-α mRNA level and 
IL-12 protein secretion were significantly decreased after PGlyRP3 
overexpression, while PGlyRP3 knocking down  induced significantly (p<0.05) 
all tested cytokine mRNA level and IL-12 secretion. These results confirm the 
anti-inflammatory role of PGlyRP3. 
 
 
Figure 5. PGlyRP3 reduces the inflammatory cytokine expression despite the 
PGNs: Caco-2 cells were transfected with PGlyRP3 plasmid or siRNA and pre-
treated with MyD88 inhibitory peptide then treated with 10 µg/ml PGN from 
different bacterial sources. After the incubation time, mRNA expression of IL-
12p35, IL-8 and TNF-α were analyzed by quantitative PCR analyses, which 
were performed using SYBR Green (A). IL-12 protein was detected using 
ELISA assay (B). Data is compared to PGN alone or with values of MyD88 
inhibitor groups. The control values of both groups (untreated Caco-2 cells or 
Caco-2 cells treated with empty plasmid, negative siRNA or control peptide) are 
mentioned in Table 2. The shown data are averages of 6 separate experiments 
performed in duplicates. Statistical analysis: *= significantly different from the 
control Caco-2 cells treated with 10 µg/ml PGN and 100 μM MyD88 inhibitory 
peptide. 
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DISCUSSION 
 PGlyRP3 protein is expressed in tissues that come in contact with the 
environment (skin epidermis, sebaceous glands, tongue, esophagus, stomach 
and intestinal tract) (35). Our previous studies showed that it is also expressed 
in intestinal epithelial cells Caco-2 cells (33). In this study we examined the 
effect of PGN from both non-pathogenic (B. subtilis and LGG), opportunistic 
pathogenic (M. luteus) and pathogenic bacteria (S. aureus) on PGlyRP3 
expression in Caco-2 cells. It is known that PGlyRP1, 3 and 4 are bactericidal 
both in vitro and in vivo against pathogenic and non-pathogenic Gram-positive 
bacteria. B. subtilis, Lactobacillus LGG (non-pathogenic bacteria) and S. aureus 
(pathogen bacterium) are equally sensitive to killing by different PGlyRPs (29).  
 The present results showed that both pathogenic, opportunistic 
pathogenic and non-pathogenic bacterial PGN time-dependently induced 
PGlyRP3 expression (Fig. 1). No difference was observed regarding the source 
of PGN. It is known that all mammalian PGlyRPs are able to bind 
peptidoglycan with high affinity, while they did not bind to other cell wall 
components (36). It is also known that human PGlyRP3 directly binds to 
bacterial PGN by two PGRP domains, each has one binding site for PGN and 
hydrophobic domains on the opposite side of the molecule from the PGN 
binding groove, which play a role in PGlyRP’s interaction with bacterial PGN 
(37, 38). The induction of PGlyRP protein production by PGN in Caco-2 cells is 
in agreement with the results of Ping et al. (39).  
 Our results agree with previous studies that PGN from different bacterial 
sources induced cytokine and chemokine expression and release (40- 42). There 
was no difference between PGN from different sources. All of them were 
inflammatory in effect. This also agrees with previous reports that pathogenic or 
non-pathogenic bacteria induced the secretion of inflammatory cytokines such 
as IL-1β, IL-6 and IL-8 in intestinal epithelial Caco-2 cells (43, 44).  
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 TLR2 has been shown to be a receptor recognizing PGN, and its 
activation in response to PGN induces the production of proinflammatory 
cytokines and chemokines (45, 46). MyD88 is an adaptor protein, which has an 
important role in the intracellular signalling stimulated by IL-1R and TLRs (47, 
48). With the exception of TLR3, all known TLRs depend entirely or partly on 
MyD88 for intracellular signalling (49). TLR2 utilizes the adaptor proteins 
MyD88 and MyD88-adaptor like (Mal) to activate IL-1 receptor-associated 
kinase. Then, the activated IL-1 receptor-associated kinase dissociates the 
MyD88/Mal complex from the receptor, followed by association with TNF-
associated factor 6 (TRAF6). This triggers the activation of the Rel family 
transcription factor NF-κB, which is required for transactivation of gene 
expression (45, 46). Our results showed that PGN from different bacterial 
strains utilizes MyD88 for TLR-pathway activation, and therefore, IL-12, IL-8 
and TNF-α expression were significantly reduced by the inhibition of MyD88. 
We suggest that PGN utilizes TLR-mediated signalling pathways to induce a 
significant inflammatory response. After stopping the TLR-pathway by 
inhibiting MyD88, PGlyRP3 overexpression reduced the PGN-induced 
inflammatory cytokines and chemokine expression (Fig. 4 and 5), while its 
silencing increased severely the PGN-induced cytokines. 
 In conclusion the present results suggest that PGN from pathogenic, 
opportunistic pathogenic and non-pathogenic bacterial sources have 
inflammatory roles mediated through activation of the TLR-pathway. There 
were no differences between PGN obtained from these different bacterial 
sources in exerting this inflammatory responses. In contrast to TLRs and NODs, 
PGlyRP3 seems to have an anti-inflammatory role in intestinal epithelial cells. 
The inflammatory effect of PGN through the TLR-pathway could be reduced by 
increasing PGlyRP3 expression and even could be turned into anti-
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inflammatory effects, if the TLR pathway is impeded. This may open 
perspectives in prevention and treatment of the inflammatory bowel disease. 
 
Table 2. Appropriate control values of various experiments. 
mRNA mRNA mRNA Protein
IL-12p35 IL-8 TNF-α IL-12
Control 1,00±0,00 1,00±0,00 1,00±0,00 94,26±1,92
LGG PGN 2,02 ±0,02 3,04±0,25 2,54±0,04 345,29±4,84
B. subtilis PGN 2,31±0,07 10,44±1,11 3,42±0,65 469,56±7,74
M. luteus PGN 3,40±0,16 5,14±0,06 2,65±0,02 389,53±8,03
S. aurues PGN 3,52±0,35 6,14±0,21 2,97±0,47 337,04±8,55
control(empty vector) 1,00±0,00 1,00±0,00 1,00±0,00 79,99±4,84
LGG PGN +PGlyRP3 plasmid 1,12±0,02 1,31±0,05 1,46±0,07 197,37±4,84
B. Subtilis PGN +PGlyRP3 plasmid 1,34±0,05 6,87±0,25 1,68±0,03 314,72±9,37
M. leutus PGN +PGlyRP3 plasmid 1,89±0,09 3,10±0,24 1,44±0,01 214,37±4,08
S. aureus PGN +PGlyRP3 plasmid 1,26±0,03 2,29±0,17 1,42±0,09 209,25±3,61
PGlyRP3 plasmid 0,72±0,22 0,59±0,05 0,49±0,07 14,56±2,21
control(NegativesiRNA) 1,00±0,00 1,00±0,00 1,00±0,00 115,16±2,84
LGG PGN +PGlyRP3 siRNA 2,90±0,14 3,33±0,11 3,25±0,03 1181,58±201,27
B. subtilis PGN +PGlyRP3 siRNA 13,70±0,52 21,68±0,39 11,75±0,29 1331,42±114,10
M. leutus PGN +PGlyRP3 siRNA 9,12±0,37 20,62±0,45 4,28±0,12 1328,16±127,44
S. aureu PGN s+PGlyRP3 siRNA 14,40±0,77 23,05±0,43 7,31±0,32 1266,99±110,37
PGlyRP3 siRNA 1,94±0,62 2,10±0,24 1,39±0,02 201,27±3,80
control negative peptide 1,00±0,04 1,05±0,02 1,02±0,04 102,24±4,73
MyD88 inhibitor 1,02±0,00 1,00±0,00 1,04±0,00 104,89±3,73
MyD88 inhibitor+LGG PGN 0,52±0,00 0,38±0,00 0,56±0,02 79,04±2,21
MyD88 inhibitor+B. subtilis PGN 0,72±0,00 0,68±0,00 0,71±0,01 69,09±1,49
MyD88 inhibitor+M. leutus  PGN 0,58±0,00 0,47±0,00 0,86±0,03 31,73±0,82
MyD88 inhibitor+S. aureu  PGN 0,62±0,00 0,59±0,00 0,63±0,00 65,81±2,79
MyD88 inhibitor+PGlyRP3 plasmid 0,44±0,00 0,48±0,00 0,46±0,00 19,72±2,68
MyD88 inhibitor+LGG PGN+PGlyRP3 plasmid 0,37±0,00 0,47±0,00 0,42±0,00 13,36±0,35
MyD88 inhibitor+B. Subtilis PGN+PGlyRP3  plasmid 0,41±0,00 0,38±0,00 0,36±0,00 16,04±2,28
MyD88 inhibitor+M. leutus PGN+PGlyRP3 plasmid 0,35±0,00 0,31±0,00 0,24±0,00 9,93±3,32
MyD88 inhibitor+S. aureu PGN+PGlyRP3 plasmid 0,23±0,00 0,24±0,00 0,26±0,005 6,80±2,43
MyD88 inhibitor+PGlyRP3 siRNA 1,03±0,02 1,00±0,00 1,058±0,02 78,96±4,75
MyD88 inhibitor+LGG PGN+PGlyRP3 siRNA 1,00±0,01 1,00±0,05 1,01±0,02 95,73±5,19
MyD88 inhibitor+B. Subtilis PGN+PGlyRP3 siRNA 0,97±0,08 0,99±0,00 1,00±0,08 109,52±6,44
MyD88 inhibitor+M. leutus+ PGN + PGlyRP3 siRNA 1,07±0,07 1,02±0,03 1,01±0,02 75,25±3,92
MyD88 inhibitor+S. aureu+  PGN+PGlyRP3 siRNA 0,99±0,01 0,98±0,00 0,96±0,02 118,03±8,45
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General Discussion 
This present study was designed to investigate the potential of nutrients 
and products of the gastrointestinal microbes to modulate immunity through the 
interaction with the pattern recognition proteins (PGlyRPs).  
It is not surprising that immunity is depending on our dietary habits. The 
gastrointestinal tract is the organ with the largest defence area and accordingly, 
it contains the largest part of the immune system, the gastrointestinal immune 
system (GI immune system). The gastrointestinal tract is a lymphoid organ, 
which consists of a lymphoid tissue known as gut-associated lymphoid tissue 
(GALT). The GALT lymphocytes are approximately equivalent in number to 
those in the spleen. The lymphoid cells in gastrointestinal tract are located in 
three basic populations according to their location, Peyer's Patches, lamina 
propria lymphocytes, and intra-epithelial lymphocytes. GI immune system has 
also other important cell types including for example the M or microfold cell. M 
cells in Peyer's Patches allow the transport of luminal microorganisms and 
macromolecules into the underlying lymphoid follicle-associated epithelium 
(FAE) where they are taken up by local dendritic cells (DC) and macrophages 
for initiation of the appropriate immune responses. On the other side, DCs 
themselves detect the presence of microbes by recruiting of pattern recognition 
receptors (PRRs) that recognize conserved pathogen-associated PAMPS, and 
are expressed on processes of the DC protruding into the gut lumen (1, 2) . The 
GI immune system is pivotal in mediating the interactions between luminal 
microbiota and host (3). In our gut, microbiota have an important role in 
nutritional and health status by improving a number of protective, immune and 
metabolic functions. The development and regulation of immune and non-
immune host defence are stimulated by gut microbiota via the interaction with 
the epithelium and the GALT (4). The balance between host protective 
immunity and regulatory mechanisms is achieved by intestinal cells, which, in 
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turn, are providing the intestinal homeostasis and acting through different 
regulatory pathways (3). This regulation depends on an input arising from the 
environment surrounding the intestinal cells comprising the bacterial and 
dietary components of the lumen, which themselves affect the microbial pattern, 
activity and metabolism.  
Our in vitro model was the Caco-2 cell line because of several reasons. 
First, the Caco-2 cell line is a suitable in vitro model of the human intestinal 
epithelium that mimics many important properties of the mucosal epithelium 
after reaching confluence. Caco-2 cells differentiate in culture and acquire 
characteristics that are both structurally and functionally similar to that of either 
crypt cells or villus cells of the small intestine (5-9). Second, the pattern of 
inflammatory responsiveness in Caco-2 cells is more similar to that of isolated 
colonocytes than most other colon cell lines. Third, stimulated cytokine 
secretion in Caco-2 cells is of a similar order of scale to that of normal isolated 
colonic epithelial cells (10-12). Finally and fortunately, we found that a gene of 
interest, a member of PGlyRP recognition pattern protein family, namely 
PGlyRP3, is expressed in this cell line and there were significant differences in 
its expression during the post-confluence days. It was also reported that 
treatment of Caco-2 cells with some bioactive food constituents like (butyrate, 
resveratrol, quercetin and curcumin) lead to changes in some genes and proteins 
expressions, which resemble in vivo observed changes. Moreover, the Caco-2 
permeability assay is considered to be the industry gold standard for in vitro 
prediction of in vivo human intestinal permeability and bioavailability of orally 
administered food and drugs (13, 14).  
Despite all of the above mentioned information about the similarity of 
this cell model to the intestinal cells, and the existence of many studies in which 
Caco-2 cells were used as an in vitro model to evaluate the gastrointestinal 
immune responses of gastrointestinal microbes (15, 16), Caco-2 cells should not 
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be considered a complete representative of the interaction between the luminal 
bacteria and the enterocytes in vivo. The gut epithelium is impermeable to 
macromolecules and microorganisms, except in Peyer's patches, where M cells 
exist, which can transport antigens and microorganisms (17). Rescigno’s group 
(18) suggested the existence of a further road for bacterial invasion. One of 
them is independent of M cells. In Caco-2–DC co-cultures, only in the presence 
of DCs bacteria were detected at the basolateral side of the Caco-2 cells, this 
suggested that bacteria cannot be transported by Caco-2 cells. Interactions 
between intestinal bacteria and the intestinal epithelium, which are also affected 
by bacterial metabolism, cannot be investigated in vitro by Caco-2 cells (19). 
Thus, Caco-2 cells do not represent the entire complexity of the in vivo system. 
Other cells are also involved such as M-cells, DCs. This point would be taken in 
consideration in our future studies. Hence, it is planned to use a mouse model 
with induced colitis to study the role of PGlyRP3 in regulation of inflammatory 
responses in intestine to the intestinal bacteria. This study may shed light on the 
importance of intestinal microbiota and provide a molecular link between 
microbiota metabolism and immune response. 
Inflammation is a special aspect of the immune response to erase local 
infections efficiently. The inflammation is affected by the immune system from 
one side and seems to be affected by nutrition from another side. There is 
abundant evidence that the intestinal microbiota have impact on the 
pathogenesis of the inflammatory diseases. Many studies have focused on the 
interference between nutrition and recognition pattern proteins, which are 
essential for the induction of inflammation. For example, it was found that the 
balance between saturated and unsaturated fatty acids influence the Toll-
mediated immune responses, which in turn can be altered by the dietary fat 
consumed. TLRs and Nods, the most studied recognition pattern proteins, could 
be activated by non-microbial molecules and they might also be involved in 
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inducing inflammation and immune responses (20-24). This might explain how 
the different types of fatty acids differentially modulate immune responses. 
Intestinal microbiota positively affect the immune response and save from the 
development of inflammatory diseases of the gut (25, 26).  
In the same context, we focused on the interference between dietary and 
microbial factors from one side, and the recognition pattern proteins PGlyRPs 
from the other side, since less is known about PGlyRPs than TLRs and Nods in 
the intestinal model.  
The metabolic products of the microbiota such as short and branched-
chain fatty acids (SCFA, BCFA) have not found much attention, although they 
have been shown to modulate the expression of various genes and reduce 
inflammation (27-30). Therefore, our research theory was based on reports 
about the ability of gastrointestinal microflora such as lactic acid bacteria to 
produce SCFA or BSFA (lipophilic products) by utilization of the prebiotic 
oligosaccharides in the intestine (31, 32). These bacterial lipophilic products 
may regulate genes of immune functions through some transcription factors 
(TFs). Although this cannot completely be confirmed only by using the in vitro 
model, we thought to test the effects of some oligosaccharides and some fatty 
acids separately on the PGlyRP3 expression in vitro and to investigate whether 
this effect takes place through a transcription factor. In parallel, we tried also to 
detect the regulatory role of PGlyRP3 in inflammation and the effects of these 
different products mentioned above.  
In contrast to the insect PGRPs, mammalian PGlyRPs have no known 
role in stimulating intracellular signalling pathways, but rather appear to act as 
antibacterial or scavenger molecules. PGlyRP3 is a novel pattern recognition 
protein, recognizing bacterial peptidoglycan and is up-regulated by bacteria and 
their products. PGlyRP3 is a bactericidal protein, which functions in 
antibacterial immunity (33, 34). Large numbers of publications have focused on 
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TLRs, Nods and PGlyRP2 as inflammatory genes and their role in inflammation 
and innate immunity. However, there is no available information about 
PGlyRP3’s role in inflammation responses. The phylogenetic analysis of all 
mammalian and insect PGRPs indicated that mammalian PGlyRP3 was derived 
from a common ancestor of PGlyRP1 (35). Because PGlyRP1 has an anti-
inflammatory role (36, 37), we assumed that PGlyRP3 may also has the same 
function. The results of the present study confirmed this assumption.  
Fatty acids or their metabolites regulate gene transcription by binding 
directly to specific transcription factors including peroxisome proliferator-
activated receptors (PPARα, β, γ1, and γ2) (38, 39). Recently, many studies 
reported that some transcription factors regulate, either directly or indirectly, 
both metabolic and inflammatory reactions at the same time (40-43). In order to 
determine common transcription factor binding sites on the PGlyRP3 promoter, 
an in silico analysis using TRANSFAC was applied. TRANSFAC is an 
internationally knowledgebase with information about experimentally-proven 
binding sites of transcription factors and regulated genes. TRANSFAC 
functions to detect genes, which are regulated by transcription factors, 
determine the binding site for any transcription factors found on these genes’ 
promoter regions and choose the specific DNA sequence(s) that bind these 
transcription factors (44). In fact, the results of the in silico analysis revealed the 
presence of many transcription factors of lipophilic ligands on the promoter 
region of PGlyRP3 gene, especially many PPARγ binding sites. PPARγ is a 
nuclear receptor involved in fatty acid intake, transport and metabolism. 
PPARγ’s role in chronic diseases was heavily investigated. It is of special 
interest that PPARγ and its ligands have been reported to exert anti-
inflammatory activities in different cell types by strongly down-regulating the 
transcription factors for many proinflammatory cytokines (45- 50). Therefore, a 
PPARγ putative binding sequence, as observed from the in silico analysis, was 
General Discussion 
 
109 
chosen to perform EMSA. EMSA is a common technique used to study protein-
DNA or protein-RNA interactions. This technique can determine whether a 
protein is able to binding to a given DNA or RNA sequence, and it can also 
indicate if more than one protein molecule is involved in the binding complex. 
To demonstrate purposes, the DNA fragment has to be labelled with a biotin, 
radioactive or fluorescent label. This method is sensitive, but, it is time 
consuming and it cannot be applied to high-throughput screening. EMSA results 
revealed the binding of PGlyRP3 gene promoter to the complex PPARγ-RXR. 
Hence, the recognition pattern PGlyRP3 protein may consequently be 
responsive to not only bacteria, but also some nutritional elements (FFAs) via 
its gene activation by the complex PPARγ-RXR. 
In our studies, we used two different artificial substances GW1929 and 
GW9662 that affect PPARγ activity. GW1929 is a PPARγ full agonist, which 
can activate PPARγ, leading to a wide-ranging gene regulation. On the contrary 
GW9662 is a potent, selective PPARγ antagonist. GW9662 covalently modifies 
and inhibit PPARγ in cell culture systems, even in the presence of high 
concentrations of reducing agent or exogenous protein (51). Different fatty 
acids were also applied in our research depending on different aspects; carbon 
chain structure (saturated, unsaturated short and branched chain FFAs), role in 
inflammation (inflammatory and anti-inflammatory FFAs), relation to PPARγ 
and FFAs sources (bacterial and dietary source). The results confirmed the 
assumed responsiveness of PGlyRP3 to the lipophilic ligands and the alteration 
in PPARγ activity. They also confirmed the link between nutritional factors and 
their transcription factors from one side, and a bacterial recognition pattern that 
leads to an immune response from the other side.  
In this study we also induced and knocked down the PGlyRP3 gene. Two 
different transfection methods have been applied. The first method was based 
on inducing PGlyRP3 plasmid DNA into Caco-2 cells. To get effective gene 
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transfer, plasmid DNA can be complexed by physico-chemical compounds 
(transfection reagents) to mediate effective transfer into the cells’ nuclei and 
then mediate subsequent protein expression of the genes of interest. We used 
lipid-based transfection reagents, which forms strong, stable, positively charged 
complexes with DNA. This prevents DNA degradation and facilitates transfer 
of the gene into the cell. This polymer provides the transfection efficiency 
despite the presence of antibiotics. The second transfection was performed by 
introducing a double-stranded RNA molecules targeting PGlyRP3 gene into 
Caco-2 cells, which in turn causes degradation of PGlyRP3 complementary 
mRNA. Small interfering RNA (siRNA) is a nucleic acid molecule used to 
silence gene expression. siRNA mediated gene silening is a quick and an easy  
method to knockdown a specific gene. It has some disadvantages, especially in 
those cells that are difficult to transfect, expensive for larger experiments and 
not useful for long term studies (52, 53).  
As proinflammatory markers, the proinflammatory cytokines IL-12 and 
TNF-α as well as the proinflammatory chemokine IL-8 were chosen. There are 
small proteins, biologically, highly active levels of them secreted in many 
different cell lines including intestinal epithelial cells. They regulate the growth, 
function, and differentiation of different cells and modulate the immune and 
inflammatory responses (54-56). It was also reported that TNF-α, IL-12 and 8 
induce intestinal inflammation, and their up-regulation is associated with 
inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis (57-
62). This suggests that these proinflammatory cytokines and chemokines play a 
key part in the regulation of the pathogenesis of inflammatory bowel disorders. 
It is also well known that various cytokines such as IL-8, IL-12p35 and TNF-α 
are expressed and secreted from intestinal epithelial cells as Caco-2 and HT29 
(63–65).  
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Gene and protein expressions of some cytokines and PGlyRP3 were 
measured after PGlyRP3 overexpression or silencing to indicate the function of 
PGlyRP3. The results showed that PGlyRP3 is not only a bactericidal gene as 
reported before in the literature (33, 34), but also has a role in the regulation of 
inflammation. PGlyRP3 has an anti-inflammatory effect per se without any 
external induction, since knocking down of the PGlyRP3 gene was sufficient to 
induce the expression of pro-inflammatory cytokines. Gene expression was 
measured by quantitative real time PCR, which is a popular technique with 
broad applications. There are  three major advantages of the PCR method: quick 
and simple since DNA cloning by PCR can be ready in a few hours using 
relatively simple tools; sensitivity since only very little amounts of target DNA 
are needed to amplify DNA sequences; and robustness since PCR allowing the 
amplification of a specific sequences from degraded or embedded DNA (66). 
The protein level was measured by ELISA or Western blotting. Western blot 
(protein immunoblot) is the technique in which particular protein could be 
detected by binding to specific antibodies. This analysis informs us about the 
size of the protein or how much protein accumulated in cells. It does not mean 
that it can do for any protein since in the case of quickly protein degradation, it 
will be hard to detect it well. The antibody is the most important constituent in 
the Western blot technique since in Western blotting it is used as a probe to 
detect specific protein. Western blotting can detect proteins in small amounts. 
But nonspecific result could be getting after reacting of an unintentional protein 
with the secondary antibody, multiple bands may also appear, bubbles may 
formed during transfer step or during the incubation with the antibodies, which 
lead to formation of a skewed band. In Western blot the transfer time should be 
sufficient, because the higher molecular weight proteins will not transfer 
properly if the transfer time was not enough, this lead to an incorrect or no band 
reading at all (67).  
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ELISA (enzyme-linked immunosorbent assay) is another technique that 
utilizes antibodies to detect the presence of a specific protein in a sample. 
ELISA showed sensitivity of 92% and specificity of 98%, quick and 
convenient, antigens of very low or unknown concentration can be detected, 
used in wide variety of tests and generally safe. ELISA has also disadvantages. 
For example, only monoclonal antibodies can be used, which is not easy to find 
and more expensive than polyclonal antibodies, enzyme-substrate reaction 
cannot stand for long time so micro-wells must be read immediately. Moreover, 
when the blocking solution is ineffective, negative controls may give positive 
results (68).  
The transcription factor NF-κB is important for the inducible expression 
of a wide variety of cellular and viral genes. NF-κB exists in an inactive form in 
the cytoplasm of most of the body cells, where it bound to the inhibitory IκB 
proteins. Treatment of cells with various inducers activates a signalling cascade 
that leads to phosphorylation of IκBs, resulting in the degradation of IκB 
proteins. This make the NF-κB dimers free to translocate into the nucleus where 
they activate the transcription of different target genes. The 5-GGGACTTTCC-
3 nucleotide sequence is the target of both homo- and heterodimers of the 
Rel/NF-κB family members (69). The activated NF-κB in the nucleus induces 
the transcription of proinflammatory genes and has been shown to be a key 
regulator of immune responses (70). The recognition of PAMPs by different 
PRRs including TLR and Nods initiates signalling cascade that activates NF-
κB. Saturated FFAs activated, while polyunsaturated FFAs inhibited NF-κB and 
thus cytokine production through TLR and Nods signalling (7-9). As PGlyRP3 
is a PRR as TLRs and Nods are, we suggested initially that PGlyRP3 modulates 
the cytokine production in the same way as both TLRs and Nods through 
activation/deactivation of the NF-κB pathway. Our results confirmed this 
assumption; PGlyR3 inhibited the NF-κB translocation through inducing IκB 
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expression. Traditionally, three different methods were used to study the 
transcription factors; EMSA, immunoblotting and reporter gene assays. These 
methods were found to be time consuming and give only semi-quantitative 
results, and they tend to lack sensitivity. So, in this study we used a new method 
called TransAM to measure the translocation of NF-κB. TransAM Kits contain 
a 96-stripwell plate which covered with an oligonucleotide containing the NF-
κB consensus-binding site (5-GGGACTTTCC-3). The active NF-κB contained 
in nuclear or whole-cell extract is added to each well, which binds specifically 
to this oligonucleotide. When NF-κB is activated a primary antibody detect NF-
κB recognizes an epitope on p65, p50 or p52. Adding a HRP- conjugated 
secondary antibody provides a colorimetric readout, which could be quantified 
by spectrophotometry. TransAM could be defined as an enzyme-linked 
immunosorbent assay (ELISA) that facilitates the study of transcription factor 
activation with a high sensitivity. TransAM assay is more sensitive than EMSA 
and is complete in a few hours. The TransAM method provides a safe 
measuring method without using radioactivity and gives quantitative results 
(69).  
Recently, it was found that the functional foods or functional food 
ingredients exert a beneficial effect on host health and reduce some chronic 
diseases (71, 72). The first generation of functional foods included thoughtful 
supplementation of food reach with minerals (mainly calcium) and vitamins 
(72). But, recently the concept has moved to food which has a positive effect on 
the gut microbiota, introducing pro- and prebiotics (73). Prebiotics are mostly 
carbohydrate fibres called oligosaccharides that feed and modulate the 
beneficial bacteria in our gut. The undigestable oligosaccharides remain in the 
digestive tract and stimulate the growth of beneficial bacteria (73). Although 
over twenty different types of oligosaccharides are on the world market today 
(74), only few studies so far have investigated the immunomodulatory effects of 
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oligosaccharides. Most of the recent oligosaccharides studies concerned about 
the role of milk oligosaccharides in the protection of the new born intestine 
against pathogenic microflora, and the ability of fructo-oligosaccharides to be 
fermented by intestinal bacteria producing SCFA, which in turn reduce the 
intestinal inflammation. However, based on the reported, not explained anti-
inflammatory role of different prebiotic oligosaccharide, we thought to 
investigate the ability of oligosaccharides to induce the expression of an 
immune gene (PGlyRP3). Two different oligosaccharides were utilized in the 
current study, which are from different origins, plant and milk, and widely used 
as prebiotics in the industry. α3-sialyllactose is the most abundant acidic 
oligosaccharide, which is present in human milk at concentrations of 0.4 to 0.8 
mg/ml; levels are much lower in bovine colostrum (0.03-0.06 mg/ml) (75). 
Recently, sialyllactose is evolving into different commercial products. It is used 
in foods especially intended for infants, children or adult as well as for medical 
foods. Raftilose p95 is a substance that is derived from chicory roots, and 
composed of 95% Fructo-oligosaccharide, mainly oligofructose (76). Raftilose 
p95 is widely used in industry as a commercial product to improve digestive 
system and bone health. Our study gives another explanation of the course of 
the oligosaccharides in the inflammation. Oligosaccharides have anti-
inflammatory roles, independently on its source (plant or milk), by enhancing a 
PPARγ-induced anti-inflammatory PGlyRP3 protein expression, which in turn, 
inhibits the pro-inflammatory cytokines expression.  
The effect of peptidoglycan (PGN), the main ligand of PGlyRPs, on the 
PGlyRP3 expression was also investigated. Many studies showed the high 
binding affinity of PGlyRP3 to PGN. Except for what was reported about the 
up-regulation of the four PGlyRPs mRNA expression and cell surface 
expression of PGlyRP3 and 4 by synthetic PAMPs (77), nothing was reported 
about PGN ability to induce PGlyRP3 expression. Administration of probiotic 
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strains led to an anti-inflammatory effect and modulated immunity (78). The 
mechanisms of this immunomodulation are still not fully understood. So, in our 
study we used different PGNs (probiotic and non-probioic bacterial PGNs) in 
order to investigate if the inflammatory role of PGN differs according to its 
bacterial source, and whether the PGNs from probiotic bacteria have anti-
inflammatory effects mediated through PGlyRP3. Unexpectedly, our study 
showed that all PGNs induce pro-inflammatory cytokines independently on its 
bacterial source, while in the same time it induces the anti-inflammatory gene 
(PGlyRP3). PGN induces these pro-inflammatory cytokines through activation 
of the TLR-pathway. These results also suggested the existence of a competition 
between the inflammatory effect of PGN through the TLR-pathway and anti-
inflammatory effect through PGlyRP3-pathway.    
The disclosure of the PGlyRP3 function in immune response is the most 
interesting conclusion of this study. We found that PGlyRP3 has anti-
inflammatory effects through the suppression of NF-κB pathway and inhibition 
of cytokine expression. The PGlyRP3 – NF-κB pathway is involved in the 
PPARγ intestinal anti-inflammatory role. PPARγ induces PGlyRP3, which 
inhibits the cytokine expression on one side and NF-κB translocation on the 
other side. In the same way, prebiotics inhibit the pro-inflammatory cytokine 
expression through the stimulation of PGlyRP3 expression. On the other hand, 
PGNs have inflammatory effects by inducing the pro-inflammatory cytokine 
expression. The inflammatory role of PGN occurs independently of PGlyRP3. 
However, the induction of PGlyRP3 reduces the inflammatory effect of PGNs. 
These results supported our hypothesis that nutrition is capable of modulating 
immunity through modulation of the recognition pattern protein (PGlyRP3). 
However, in the current study the role of epithelial PGlyPR3 in inflammation is 
exclusively investigated in an in vitro context. Thus, it is preliminary to 
conclude for the role of PGlyPR3 in real life intestinal inflammations. So, in 
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future studies we should provide evidences that epithelial PGlyPR3 has an in 
vivo role in intestinal inflammation by using appropriate in vivo model. We 
would also investigate the role of PGlyRP3 in ulcerative colitis as a step to 
indicate the role of PGlyRP3 in different inflammatory diseases in human. 
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